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A comprehensive summary of the work to be incorporated in the thesis entitled 
“STUDIES ON HETEROCYCLIC COMPOUNDS OF MEDICINAL   INTEREST” 
has been described as under. 
 
PART-A: STUDIES ON PYRAZINE DERIVATIVES 
PART-B: STUDIES ON 6-CHLORO-INDOLE DERIVATIVES 
 
PART-A: STUDIES ON PYRAZINE DERIVATIVES 
The development of our understanding of disease processes and the resulting 
discovery of new drugs for their treatment has improved the quality of life throughout the 
world. The primary goal of the our research work is to find and develop new chemical 
entities (NCEs) which can be used against untreatable diseases, or which have superior 
properties when compared to currently available drugs.  
Pyrazine nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products. Many pyrazine derivatives 
have displayed diverse pharmacological activities like anti-inflammatory, antitumor, 
calcium channel blocker etc. In view of our on going interest in the synthesis of some 
new potentially bioactive pyrazine derivatives have been described as under. 
 
PART-I: STUDIES ON 2-(PIPERIDIN-4-YLMETHOXY)PYRAZINE DERIVATIVES 
 The synthesis of compound 2-(piperidin-4-ylmethoxy)pyrazine derivatives has 
been attracted widespread attention due to their diverse pharmacological properties like 
anti-inflammatory, antibiotic, antifungal, herbicidal, antitubercular, etc. To approach this 
goal, the synthesis of some new 2-(piperidin-4-ylmethoxy)pyrazine derivatives have been 
undertaken.  
 
SECTION-I: Synthesis and biological evaluation of Aryl{4-[({5-[3-
(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-yl}methanones 
 
 
 
 
 
Studies on hetrocyclic… 
Synopsis…                                                                                                                            2 
N
N
O
N
O
R
S
O
O
CH3
 
R=Aryl  
Type (I) 
 
 2-(Piperidin-4-ylmethoxy)pyrazines derivatives of Type (I) have been synthesized 
by the condensation of 2-[3-(methylsulfonyl)phenyl]-5-(piperidin-4-ylmethoxy)pyrazine 
with various aromatic acid chlorides in the presence of TEA. 
 
SECTION-II: Synthesis and biological evaluation of Aryl[4-({[5-(2-
fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]methanones 
 
N
N
O
N
O
R
F  
R=Aryl  
Type (II)  
 
 2-(Piperidin-4-ylmethoxy)pyrazines derivatives of Type (II) have been 
synthesized by the condensation of 2-(2-fluorophenyl)-5-(piperidin-4-ylmethoxy)pyrazine 
with various aromatic acid chlorides in the presence of TEA. 
 
SECTION-III: Synthesis and biological evaluation of Aryl[4-({[5-(thiophen-2-
yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]methanones 
 
N
N
O
N
O
R
S  
R=Aryl  
    Type (III)   
 
2-(Piperidin-4-ylmethoxy)pyrazines derivatives of Type (III) have been 
synthesized by the condensation of 2-(piperidin-4-ylmethoxy)-5-(thiophen-2-yl)pyrazines 
with various aromatic acid chlorides in the presence of TEA. 
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SECTION-IV: Synthesis and biological evaluation of Aryl[4-({[5-(1-benzothiophen-
3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]methanones 
 
S
N
N
O
N
O
R
 
R=Aryl  
 Type (IV)  
 
 2-(Piperidin-4-ylmethoxy)pyrazines derivatives of Type (IV) have been 
synthesized by the condensation of 2-(1-benzothiophen-3-yl)-5-(piperidin-4-
ylmethoxy)pyrazines with various aromatic acid chlorides in the presence of TEA. 
 
PART-B: STUDIES ON 6-CHLORO-INDOLE DERIVATIVES 
Heterocyclic compounds bearing 6-chloro-indole ring system are endowed with 
variety of biological activities. Our strategy is based on to develop a new bioactive entity 
especially with pharmacological activities bearing heterocyclic ring system. Literature 
survey reveals that nitrogen containing heterocyclic compounds like 6-chloro-indole have 
received considerable attention in medicinal science due to their biological and 
pharmacological activities like anticancer, anti-inflammatory, herbicidal, hypnotic, 
sedative, antimicrobial, antitubercular, antithyroid and many other therapeutic activities. 
 
PART-I: STUDIES ON 6-CHLORO-INDOLE-5-CARBOXYLATE DERIVATIVES 
The discovery of 6-chloro-indole-5-carboxylate derivatives as potent biologically 
active agent has led to the exploration of large number of structural variants, containing 
6-chloro-indole-5-carboxylate moiety as an invariable ingredient. Its derivative has shown 
various biologically activities such as anticancer, anathematic, antimicrobial, 
antihistamine, anti-inflammatory, antibacterial etc. In order to develop therapeutically 
important compounds, it was consider of interest to synthesize some 6-chloro-indole-5-
carboxylate shown as under. 
 
SECTION-I: Synthesis and biological evaluation of Methyl 6-chloro-3-[(N,N-
dialkylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxylates 
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R=Secondary amine  
Type (V)  
 
6-Chloro-indole-5-carboxylate derivatives of Type (V) have been synthesized by 
the condensation of methyl 6-chloro-1-methyl-1H-indole-5-carboxylate with oxalyl 
chloride and different secondary amine in the presence of DCM. 
 
SECTION-II: Synthesis and biological evaluation of Methyl 1-benzyl-6-chloro-3-[( 
N,N-dialkylamino)(oxo)acetyl]-1H-indole-5-carboxylates 
 
N
O
O
Cl
O
O
CH3
R
 
R=Secondary amine  
Type (VI)  
 
6-Chloro-indole-5-carboxylate derivatives of Type (VI) have been synthesized by 
the condensation of methyl 1-benzyl-6-chloro-1H-indole-5-carboxylate with oxalyl 
chloride and different secondary amine in the presence of DCM. 
 
PART-II: STUDIES ON 6-CHLORO-INDOLE-3-YL-GLYOXYLAMIDE 
DERIVATIVES 
6-Chloro-indole-3-yl-glyoxylamide moieties represent important building blocks 
in both natural and synthetic bioactive compounds, which have been shown to possess 
diverse therapeutic activities The nature and the position of the substituent on the indole 
moiety influence these activities. Molecules containing 6-chloro-indole-3-yl-
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glyoxylamide has been shown to have a broad range of important biological activities 
including anticancer, antibacterial, antimicrobial, anti-inflammatory, antitubercular etc. 
 
SECTION-I: Synthesis and biological evaluation of 6-Chloro-3-
[(diethylamino)(oxo)acetyl]-1-methyl-N-aryl-1H-indole-5-carboxamides 
 
N
O
O
N
CH3
Cl
O
NH
R
CH3 CH3
 
R=Aryl  
Type (VII)  
 
6-Chloro-indole-3-yl-glyoxylamide derivatives of Type (VII) have been 
synthesized by the condensation of 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-
indole-5-carboxylic acid and different aryl amine in the presence of DCC, HOBT and 
TEA. 
 
SECTION-II: Synthesis and biological evaluation of 6-Chloro-3-
[(diethylamino)(oxo)acetyl]-1-benzyl-N-aryl-1H-indole-5-carboxamides 
 
N
O
O
N
Cl
O
CH3
NH
R
CH3
 
R=Aryl  
Type (VIII)  
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6-Chloro-indole-3-yl-glyoxylamide derivatives of Type (VIII) have been 
synthesized by the condensation of 1-benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1H-
indole-5-carboxylic acid and different aryl amine in the presence of DCC, HOBT and 
TEA. 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the compounds have been evaluated for their antibacterial activity towards 
Gram +ve and Gram -ve bacterial strains and antifungal activity towards Aspergillus 
niger at a concentration 40 µg/ml. The biological activities of the synthesized compounds 
have been compared with standard drugs. 
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INTRODUCTION 
Pyrazine contains two nitrogen atoms in its aromatic ring.1 Pyrazine play an 
important role as intermediates for perfumes,2 pharmaceuticals, agricultural chemicals3 
and food spices. Especially, amides and sulfonamides of pyrazines have been used on 
various topics as anti-tuberculosis, dyes and pigments,4 oral anti diabetics, nutrition 
supplement, insecticides and fungicides. 
 
N
N
1
2
3
4
5
6
 
 
In general pyrazine is prepared by the catalytic reaction of diamines with dioles in 
a vapour phase, dehydrogenation of piperazine or dealkylation of methyl pyrazine. 
Pyrazine and their derivatives form an important class of compounds present in several 
natural flavors and complex organic molecules, it is also responsible for flavor in 
foodstuffs, like cheese, tea coffee, cooked meats nice aroma etc.5  
 
SYNTHETIC ASPECT 
Various methods for the preparation of pyrazine derivatives have been cited in 
literature, some of them are as under. 
1. The pyrazine derivatives have synthesized by direct conversion of α-hydroxy 
ketones and α-keto oximes in the presence of a catalytic amount of ceric 
ammonium nitrate was reported by A. Shaabani et al.6 
 
O
OH
R
R
NC
NH2NC
NH2
+
CAN, Air
H2O, rt., 45 min
N
N
NC
NC
R
R
 
 
2. B. M. Latha et al.7 have synthesized pyrazine from ethylenediamine on copper 
oxide/copper chromite catalysts. 
 
NH2
NH2 N
H
N
H
2 -2NH3
-3H2
N
N
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3. Microwave-assisted synthesis of pyrazine derivatives from α-halo ketone in 7% 
NH3 solution was given by T. Utsukihara et al.8 
 
OR
1
R
2
X
7 % NH3 aq
Microwave
N
N
R
1
R
2
R
2
R
1
 
 
4. Synthesis of 2-methyl pyrazine from zinc-modified ferrierite (FER) catalysts was 
documented by R. Anand et al.9 
 
NH2
NH2
CH3
OH
OH
+
N
H
N
H
CH3
Intermolecular 
cyclization
deyhdrogenation
Zno-FER
N
N CH3
 
 
5. W. T. Reichle et al.10 have given the synthesis which involve the reaction of 
diketones with appropriate diamines, which gave the diazine which readily 
oxidized to the pyrazines.  
 
O
O
+
NH2
NH2
N
N
N
N
-2H2O -H2
 
 
 
THERAPEUTIC IMPORTANCE 
Over recent years there has been an increasing interest in the chemistry of 
pyrazine derivatives because of their biological significance. 
1. Analgesic11 
2. Antiallergic12 
3. Antibacterial13 
4. Anti-inflammatory14 
5. Antiviral15 
6. Diuretic16 
7. Anticancer17 
8. Anti HIV18 
9. Anti hypertensive19 
10. Cardiovascular20 
Studies on heterocyclic… 
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11. Antioxidant21 
12. Antimycobacterial22 
 
 L. E. Seitz et al.23 have synthesized and evaluated antimycobacterial activity of 
pyrazine derivatives (1). H. Foks et al.24 have synthesized and screened antibacterial 
activity of 1H-pyrazolo[3,4-b]pyrazine derivatives.  
 
N
N
O
R
1
R1 = aryl
(1)  
 
Pyrazine derivatives (2) with an allylsulfur moiety have hepatoprotective effects 
against toxicants. Effect of 2-AP on hepatic tumorigenesis in association with glutathione 
S-transferase (GST) induction was examined in rats exposed to aflatoxin B1 (AFB1) was 
given by T. G. Ha et al.25 
 
N
N S
CH2
(2)      
 
H. Foks et al.26 have synthesized and checked tuberculostatic activity of 4-
substituted 3,4,5,6-tetrahydro-2H-[1,2']-bis-pyrazine derivatives (3). F. Micheli et al.27 
have synthesized pyrido [2,3-b] pyrazine-8-oxide derivatives as selective glycine 
antagonist with in vivo activity. 
 
N
N
N
S
Ph
N
N
R
1
R1 = Ph, CH2Ph, Pyridine
(3)
 
 
Synthesis and evaluation of substituted N-phenylpyrazine-2-carboxamides (4) as 
herbicides and abiotic elicitors was reported by M. Dolezal et al.28 
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N
N O
NH
CH3
CH3
CH3
R
1
R1 = Cl, I, F, CF3(4)
 
 
K. Zurbonsen and coworkers29 have studied antiproliferative, differentiating and 
apoptotic effects elicited by imidazo[1,2-a]pyrazine derivatives (5). T. Yanai et al.30 have 
synthesized novel pyrazine compounds produced from chitin by the activity of the 
enzyme from vibrio alginolyticus TK-24. 
 
N
N N
R
2
R
1
R
4
R
3
R1 = H, Br 
R2 = Br, NH2, NHCH3, NHCH2CH3  
R3 = CN, H
R4 = H, Br, CH2OH, CH2OCH3(5)  
 
Pyrazine derivatives (6) tested against human keratinocyte cells stressed UVB 
irradiation showed high anti oxidative properties was given by J. Cavalier et al.31 
 
R1 = R2 = R3= OH, OCH3 
N
N
NH2
R
1
R
3
R
2
(6)  
 
B. A. Ellsworth et al.32 have studied structure activity relationships for a series of 
pyrazine carboxamide (7) as CB1 antagonists. Pharmaceutical properties of the series (7) 
were improved via inclusion of hydroxyl containing side chains. This structural 
modification sufficiently improved ADME properties of an orally inactive series such that 
food intake reduction was achieved in rat feeding models. 
 
N
N
CH3
CH3
O
R
1
(7)
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J. W. Corbett et al.33 have synthesized indanylpyrazines (8) and reported 
corticotrophin releasing factor type-1 receptor antagonists. 
 
N
NR
1
NH
R
2
R
3
NH
N
R1 = R3 = CH3, C2H5
R2 = Propyl(8)
 
 
N. Sinha et al.34 have synthesized and screened antimycobacterial activity of some 
pyrazine derivatives (9). K. Yoshiizumi et al.35 have synthesized and studied structure 
activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine based hydroxamic acids 
as HB-EGF shedding inhibitors. 
 
N
N
O
N
NH Ar
O
N
(9)
 
 
Pyrazin-2-yl-formamide thiosemicarbazones (10) related to their tuberculostatic 
activity was reported by A. Olczak et al.36 
 
N
N
NH2
HNN
S
R
1
R1 = secondary amine
(10)  
 
The novel structures 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-
dicarbonitriles (11) and their promising protein kinase inhibitors with antiproliferative 
activity was given by G. G. Dubinina et al.37 
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N
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N
N
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N
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NC
NC
R
1
S OO
X = NH, N-CH3, N-CH2Ph, S
(11)
 
 
Synthesis and tuberculostatic activity of pyrazinyl substituted derivatives (12) was 
reported by H. Foksi et al.38 
 
N
N
N
S
N
R
1 R
2
R1 = R2 = secondary amine
(12)  
 
J. Bostrom et al.39 have studied scaffold hopping, synthesis and structure activity 
relationships of 5,6-diaryl-pyrazine-2-amide derivatives (13) of CB1 receptor antagonists. 
 
N
N
Cl
Cl
Cl
O
NH
N
(13)  
 
Synthesis and biological activity of 5-aroylpyrazine-2-carboxylic acid derivatives 
(14) was given by M. Dolezal et al.40 
N
N
R
1
O
R
2
R1 = CN, CONH2
R2 = H, OH, Cl(14)
 
 
M. Dolezal et al.41 have synthesized and reported antimycobacterial evaluation of 
substituted pyrazine carboxamide derivatives (15). 
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N
N
NH
O
X
R
1
R
2
R1 = H, tert-butyl
R2 = CH3, CF3, F, Cl
X = H, Cl(15)
 
 
J. Krinkova et al.42 have synthesized and evaluated biological activity of 5-alkyl-
6-(arylsulfanyl)pyrazine-2- thioamides derivatives (16). 
 
N
NR
1
CSNH2SR
2
R1 = C3H7, C4H9
R2 = CH3, C2H5, C3H7, C4H9, C6H5(16)
 
 
C. G. Bonde coworkers43 have synthesized and given preliminary evaluation of 
some pyrazine derivatives (17) as antimicrobial agents. 
 
N
N
O
NH
O
N S
N
OR
1(17)
 
 
T. Asaki et al.44 have studied structure activity on diphenylpyrazine derivatives 
(18) of prostacyclin receptor agonists. 
 
N
N
Ph
Ph N
R
1
O
O
OH
R1 = ethyl, allyl, cyclopropyl
(18)
 
Synthesis and antiinflammatory activity of methyl substituted imidazo[1,2-
a]pyrazine derivatives (19) was reported by M. G. Rimoli et al.45 
 
N
N N
R
1
R
2 R
1 = CH3, CH2COOH, COOH
R2 = H, COOH(19)
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Synthesis of two new hybrid metal-organic polymers using flexible pyrazine 
crystal structures was given by C. Zhang et al.46 Synthesis and biological evaluation of 
pyrido[2,3-b]pyrazine-N-oxide as selective glycine antagonists was reported by A. 
Cugola et al.47 J. E. Dowling et al.48 have synthesized of [1,2,4]triazolo[1,5-a]pyrazines 
as adenosine A2A receptor antagonists. C. A. Hargreaves and coworkers49 have studied 
tetrahydropyrido[2,3-b]pyrazine scaffolds. H. Mukaiyama et al.50 have synthesized and 
given C-SRC inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for 
treatment of acute ischemic stroke. D. R. Owen et al.51 have studied structure activity 
relationships of pyrazine derivatives as a novel non competitive mGluR1 antagonists. 
Synthesis and antimycobacterial activity of pyrazine derivatives documented by L. E. 
Seitz et al.52 Imidazo[1,2-a]pyrazine shows the bronchodilatory and cyclic nucleotide 
phosphodiesterase inhibitory activities was given by T. O. Vitse et al.53 
Thus the important role displayed by pyrazine and its derivatives for various 
therapeutic and biological activities prompted us to synthesize some pyrazine moiety in 
order to achieve compounds having better therapeutic activities summarized in the part as 
under.  
 
 
STUDIES ON PYRAZINE DERIVATIVES 
 
PART-I: STUDIES ON 2-(PIPERIDINE-4-YLMETHOXY)PYRAZINE 
DERIVATIVES  
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INTRODUCTION 
Pyrazine nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products. In view of our ongoing 
interest in the synthesis of some new potentially bioactive pyrazine derivatives (1) have 
been described as under. 
 
N
N
O
N R
2
R
1
(1)  
 
The synthesis of compound 2-(piperidin-4-ylmethoxy)pyrazine derivatives has 
been attracted widespread attention due to their diverse pharmacological properties like 
anti-inflammatory, antibiotic, antifungal, herbicidal, antitubercular, etc. To approach this 
goal synthesis of some new 2-(piperidin-4-ylmethoxy)pyrazine derivatives have been 
undertaken.  
 
 
SYNTHETIC ASPECT 
Various methods of bromination, diazotization, mitsunobu reaction, suzuki cross 
coupling and deprotection of pyrazine derivatives have been cited in literature, some of 
the methods are as under. 
BROMINATION 
1. Bromination of 2-amino pyrazine in presence of bromine and pyridine in CHCl3 
was given by S. Sevilla et al.1 
 
N
N NH2
N
N NH2
BrBr
CHCl3
Br2, pyridine
 
 
2. F. D. Weal et al.2 have synthesized 2-amino-5-bromopyrazine from pyrazine, N-
bromosuccinamide in acetonitrile solution. 
 
N
N NH2
NBS, CH3CN
overnight, rt
N
N NH2
Br
 
 
Studies on heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                         19 
3. Pyrazine react with N-bromosuccinamide in DMSO solution to give 3,5 dibromo 
pyrazine was reported by B. Jiang et al.3 
 
N
N NH2
NBS, DMSO N
N NH2
BrBr
 
 
4. A. M. Stadler et al.4 have synthesized 2-amino-5-bromopyrazine from pyrazine, 
N-bromosuccinamide in CH2Cl2 solution.  
 
N
N NH2
NBS
N
N NH2
Br
CH2Cl2
 
 
5. Bromination of 2-amino pyrazine from pyrazine and brominating agent was given 
by T. Itoh et al.5    
 
N
N NH2
N
N NH2
Br
brominating agent +
N
N NH2
BrBr
 
 
DIAZOTIAZITION  
6. Preparation of 5-bromopyrazin-2-ol from 2-amine-5-bromopyrazin, NaNO2 and 
H2SO4 was reported by F. Jing et al.6 
 
N
N NH2
Br H2SO4, NaNO2
N
N OH
Br
 
 
7. H. Mukaiyama et al.7 have prepared 5-bromopyrazin-2-ol from 2-amine-5-
bromopyrazin, NaNO2 and CH3COOH in dioxane solution.  
 
N
N NH2
Br
CH3COOH, NaNO2
N
N OH
Br
dioxane
 
 
8. S. Nobuhiro et al.8 have studies diazotization of 2-amine-5-bromopyrazin in 
sulphuric acid and sodium nitrate. 
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N
N NH2
Br H2SO4, NaNO2
N
N OH
Br
20 min 5 oC, 40 min 40 oC
 
 
9. H2SO4 and sodium nitrate react with 2-aminopyrazine to gave 2-hydroxypyrazine 
was given by Y. Jun et al.9 
 
H2SO4, NaNO2
H2O
N
N NH2
Br
Cl
N
N OH
Br
Cl
 
 
10. A. E. Erickson et al.10 have synthesized 5-bromopyrazin-2-ol from 2-amine-5-
bromopyrazin, NaNO2 and H2SO4.  
 
H2SO4, NaNO2
N
N NH2
N
N OH 
 
MITSUNOBU REACTION 
11. Use of sonication for the coupling of sterically hindered substrates in the phenolic 
mitsunobu reaction was reported by S. D. Lepore et al.11 
 
OH
OCH3
O
+ OH
sonication
DIAD, PPh3
THF, 25 oC, 15 min
O
OCH3
O
 
 
12. Organocatalytic mitsunobu reaction of phenol and acid in THF was documented 
by T. Y. S. But et al.12 
 
DEAD, PPh3
O
OH
O2N
+
OH
Ph
THF
O
O
O2N
Ph
 
 
13. Di-p-chlorobenzyl azodicarboxylate (DCAD) was introduced as a novel, stable 
and solid variety of mitsunobu coupling in CH2Cl2 was given by B. H. Lipshutz et 
al.13 
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OH
+
O
OH OCH3
H3CO
DCAD, PPh3
CH2Cl2, rt
O
O OCH3
H3CO  
 
14. Carbon nucleophiles in the mitsunobu reaction, mono- and dialkylation of 
bis(2,2,2-trifluoroethyl) malonates was given by J. M. Takacs et al.14 
 
R
1
OH +
H
COOCH2CF3
COOCH2CF3
H Mitsunobu conditions
R
1
COOCH2CF3
COOCH2CF3
H  
 
15. Second-generation tags for fluorous chemistry exemplified with a new fluorous 
mitsunobu reagent and fluorous triphenylphosphine in THF was reported by Q. 
Chu et al.15 
 
OH
CN
+
OH
F
N N
O(CH2)3O-t-C4F9
O O
t-C4F9O(CH2)3O
F-TPP, THF
NC O
F
 
16. Multipolymer solution-phase organocatalytic mitsunobu reaction of phenol and 
acid in THF was reported by A. M. Harned et al.16 
 
OTPP, HO-DEAD
O
OH
O2N
+
OH
Ph
THF
O
O
O2N
Ph
 
 
SUZUKI CROSS COUPLING 
17. Microwave-assisted efficient copper-promoted N arylation of amines with 
arylboronic acids was given by S. Chen et al.17 
 
NHO + PhB(OH)2
Cu(OAc)2, DBU
DMSO, MW
ONPh
 
 
18. Stepwise cross-coupling reactions in pyrazine derivatives was reported by C. 
Yang et al.18 
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N
N
Br
NH2
OCH3
+
Pd(PPh3)4
2 M Na2CO3
N
N NH2
OCH3Ph
PhB(OH)2
 
 
19. A novel and versatile entry to asymmetrically substituted pyrazines was reported 
by V. P. Mehta et al.19 
 
N
N
X
S
R
2
R
1
+
Pd(PPh3)4, K2CO3PhB(OH)2
N
N
Ph
S
R
2
R
11,4-dioxan : H2O (1:1)
MW
 
 
20. Microwave-assisted synthesis C-C bond formation of pyrazine derivatives was 
documented by S. Sevilla et al.1 
 
N
N
Br
NH2
NH
R
1
+
Pd(dppf)2Cl.DCM
N
N
Ar
NH2
NH
R
1
toluene : EtOH (2:1), 90 oC
ArB(OH)2
 
 
21. Palladium imidazolium carbene catalyzed aryl, vinyl and alkyl suzuki-miyaura 
cross coupling synthesis was given by M. B. Andrus et al.20 
 
Ar N2
+
BF4
-
+ R
1
-B(OH)2
Pd(OAc)2, THF
N N
+
i-Pr
i-Pr
i-Pr
i-PrCl
- Ar R
1
 
 
22. New coupling partners in room temperature suzuki reaction of alkyl bromides 
under remarkable mild conditions was reported by J. H. Kirchhoff et al.21 
 
R
1
Br
+ R2-B(OH)2
5 mol-% Pd(OAc)2, P(tBu)2Me
KOtBu, t-amyl alcohol
R
1
R
2
 
 
23. S. Li et al.22 have synthesized Pd(OAc)2-catalyzed room temperature suzuki cross-
coupling reaction in aqueous media under aerobic conditions.  
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+ Ar'-B(OH)2
Pd(OAc)2, K2CO3
EtOH : H2O (2:3), 80 
oC
Ar-X Ar Ar'
 
 
24. C. Baillie et al.23 have synthesized and given its applications in the suzuki-
miyaura coupling of aryl chlorides in presence of ferrocenyl monophosphine 
ligand in dioxane. 
 
+ Ar'-B(OH)2
Pd(OAc)2
K3PO4, dioxane, 95 
oC
Ar-Cl Ar Ar'
Ferrocenyl monophosphine ligand
 
 
25. Suzuki-miyaura cross-coupling reaction under ligand free conditions was given by 
W. J. Liu et al.24 
+ Ar'-B(OH)2
Pd(OAc)2, TBAB, K2CO3
PEG-400, 110 oC
Ar-X Ar Ar'
 
 
26. Phosphine free palladium acetate catalyzed suzuki reaction in water was given by 
L. Liu et al.25 
 
+ Ar'-B(OH)2
Pd(OAc)2, Na2CO3
H2O/PEG-2000 (6:7), 50 
oC
Ar-X Ar Ar'
 
 
27. A highly active catalyst for suzuki-miyaura cross coupling reactions of heteroaryl 
compounds was reported by K. L. Billingsley et al.26  
 
+ HetAr'-B(OH)2
Pd(OAc)2, K3PO4, n-butanol, 100 
oC
Ar-X Ar Ar'
R
1
R
3
R
2 PCy2  
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28. Y. M. A. Yamada et al.27 have prepared highly active catalyst for the 
heterogeneous suzuki-miyaura reaction by assembled complex of palladium and 
non-cross-linked amphiphilic polymer. 
 
+ R2-B(OH)2
(ArPh2P)2PdCl2R1-X
Na2CO3, H2O, 100 
oC
R
1
R
2
 
 
 DEPROTECTION 
29. B. Li et al.28 have used aqueous phosphoric acid is an effective, environmentally 
benign, selective and mild reagent for the deprotection of tert-butyl carbamates. 
 
R
1
N O
O
R
2
H3PO4
toluene, rt
R
1
NH
R
2
 
 
30. A stereo conservative deprotection method of amino groups was reported by D. 
M. Shendage et al.29 
NH
CH3
NH
O
CH3
O
O
HCl-MeOH
rt, 1 h
NH2
CH3
NH
O
CH3
 
 
31. Selective removal of the tert-butoxycarbonyl group from secondary amines using 
zinc bromide as the deprotecting reagent was given by S. C. Nigama et al.30 
 
N
O
O ZnBr2, CH2Cl2 NH
 
 
32. N. B. Narasimhulu et al.31 have studied deprotection of piperidine derivatives 
from tert-butyl piperidine and TFA in chloroform solution. 
 
CF3COOHN
O
O
CH2 NHCH2CH2Cl2, rt 
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33. Reaction of tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate in HCl in 
dioxane solution to gave 4-(prop-2-yn-1-yl)piperidine was prepared by N. D. 
Waal et al.32 
 
HCl in dioxaneN
O
O
CH
NH
CH
 
 
34. F. Bois et al.33 have studies deprotection of (2S)-2-methylpiperidine from tert-
butyl (2R)-2-methylpiperidine-1-carboxylate, CF3COOH and anisole in 
dichloromethane solution. 
 
CF3COOH
N
O
O
CH3
NH
CH3
PhOMe, CH2Cl2
 
 
REACTION MECHANISM OF MITSUNOBU  
 
Ph3P
..
N N
EtO2C
CO2Et
+ .. .. N N
-
EtO2C
CO2EtPh3P
+
..
N N
EtO2C
CO2EtPh3P
+
H
+
R
O
+
H
P
NPh3
EtO2C
N
H
CO2Et
-
O
O
H
R
O H
..
R
O
+
Ph3P
+H
+
+N N
-
EtO2C
CO2EtH
N N
EtO2C
CO2EtH
H
+
R
O
+
Ph3P
-O=PPh3
+O
-
O
R
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REACTION MECHANISM OF DEPROTECTION  
 
O N
O
R
H
H
+
O N
+
O
R
H H
N H
H
R
+ CO2 +
+
 
 
 
REACTION MECHANISM OF SUZUKI COUPLING 
 
Pd(II) R1R2
Pd(0)
R2-X
Pd(II) XR2
Pd(II) O
t
BuR2
NaO
t
Bu
NaX
R1 B
Y 
Y 
B
-
O
t
Bu
Y 
Y 
R1
B
-
O
t
Bu
Y 
Y 
Bu
t
O
Na
+
R1 R2
NaO
t
Bu
 
 
 
THERAPEUTIC IMPORTANCE 
 2-(Piperidine-4-yl methoxy)pyrazine derivatives have been tested for various 
pharmacology activities, which have been summarized as under. 
1. Analgesic34 
2. Antibacterial35 
3. Antifungal36 
4. Anti-inflammatory37 
5. Antiviral38 
6. Anticancer39 
7. Anti HIV40 
 
A. V. Shindikar et al.41 have designed, synthesize, and in vivo activity tested in 
mice against mycobacterium tuberculosis H37Rv of pyrazine derivatives (2). K. J. French 
et al.42 have studied cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine based inhibitors of 
human N-myristoyltransferase-1. 
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D. Sriram et al.43 have synthesized pyrazinamide derivatives (3) and reported 
antitubercular properties. D. C. Scopes et al.44 have synthesized new k-receptor agonists 
based upon a 2-[(alkylamino)methy]piperidine nucleus. 
 
N
N
NH
O
N
N
R
1
(3)  
 
 
Synthesis, anticancer, anti-inflammatory and analgesic activity evaluation of 
some pyrazine derivatives (4) reported by S. M. Sondhi et al.45 B. S. Huegi et al.46 have 
synthesized and reported pharmacological studied of 4,4-disubstituted piperidine 
derivative as a potent analgesic properties. 
N
N
X
N N
S
(4)  
 
B. C. Gordon et al.47 have synthesized pharmaceutical composition containing 
piperidine derivatives (5) and doccumented their use as modulators of chemokine CCR5 
receptors. Synthesis and analgesic activity of some spiro[dibenz[b,f]oxepin]-10,4’-
piperidine] derivatives was reported by H. H. Ong et al.48 
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R
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Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine 
derivatives (6) was given by R. Weis et al.49 A. Z.  Kabdraisova et al.50 have reported 
synthesis and biological activity of N-(2-thoxyethyl)piperidine derivatives of anabasin. 
Synthesis and biological screening of some piperidine substituted benzimidazoles was 
reported by V. Sundari et al.51 A. Seza et al.52 have studied antimicrobial activity of some 
piperidine substituted halogenobenzene derivatives. 
 
N
CH3
O H
(6)
 
 
S. J. Philippe et al.53 have prepared piperidine derivatives (7) and tested antibiotics 
activity. Effect of substituents on N-(1-piperidinobenzyl)acetamide and their 
antimicrobial activity was reported by N. Raman et al.54 M. Yoshifumi et al.55 have 
studied antimicrobial and anti-plaque activity of N’-alkyl-N-(2-aminoethyl)piperidine 
against dental plaque bacteria. 
 
N
M
R
4
R
3
YX
R
2
R
1
(7)   
 
Synthesis and structure activity relationships of 2-phenyl-1-[(pyridinyland 
piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols (8) as antifungal agents 
was given by F. Giraud et al.56 K. K. Goel et al.57 have synthesized and screened for 
antimicrobial activity of piperidin-4-one derivatives. K. Canan et al.58 have synthesized 
and tested antimicrobial activity of some nove 2-[4-(substituted piperidin-1-
ylcarbonyl)phenyl]-1H-benzimidazole derivatives.    
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R1 = H, BOC
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M. Ishikawa et al.59 have synthesized and given structure activity relationships of 
N-aryl-piperidine derivatives (9) as potent (partial) agonists for human histamine H3 
receptor. M. Tibor et al.60 have studied histamine H3 receptor antagonists of 1-(4- 
Phenoxymethyl) benzyl)piperidines derivatives. 
 
N
H
N
N
R
1
R1 = H, CF3, C(CH3)3, F, NO2, 
CH(CH3)2, OCH3, NHCH3, N(CH3)2
(9)
 
 
G. D. Maynard et al.61 have synthesized and given SAR of 4-(1H-benzimidazole-
2-carbonyl)piperidines (10) with dual histamine H1/tachykinin NK1 receptor antagonist 
activity. A. G. Magid et al.62 have synthesized substituted piperidine derivatives as novel 
H1-antagonists. V. Claudio et al.63 studied antinociceptive profile of 2,3,6-trisubstituted 
piperidine alkaloids. 
N
O
N
N
R
3
N
O
R
1
R
2
R1 = 3,4,5-(OCH3)3
R2 = 3,4-(OCH3)2, OCH3, CF3, F, Cl
R3 = aryl(10)
 
 
C. E. Gutteridge et al.64 have studied N-(3-phenylsulfonyl-3-piperidinoyl)-
phenylalanine derivatives (11) as potent, selective VLA-4 antagonists. Study of piperidine 
carboxylic acid derivatives of 10H-pyrazino[2,3-b][1,4]benzothiazine as orally active 
adhesion molecule inhibitors investigated by K. Toshihiko et al.65 
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C. G. Barber et al.66 have investigated 1-amino-1-phenyl-3-piperidinylbutanes 
(12) CCR5 antagonists for the treatment of HIV. Analgesic and antiinflammatory activity 
screening of 6-acyl-3-piperidinomethyl-2(3H)-benzoxazolone derivatives was reported by 
E. D. Demir et al.67 
 
 
 
 
 
 
 
 
 
S. Imamura et al.68 synthesized and reported biological evaluation of piperidine-4-
carboxamide derivatives (13) as CCR5 antagonists as anti-HIV-1 agents. Synthesis and 
biological activity of piperidinoaryl carbamides and their derivatives was reported by V. 
M. Gujrati et al.69 W. Tao et al.70 have synthesized diketopiperidine derivatives as HIV 
attachment inhibitors and reported, pharmaceutical compositions and use in the treatment 
of HIV infection and AIDS. 
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R1 = COCH3, SO2CH3
R2 = H, Cl, CH3, OCH3
R3 = H, F(13)
 
 
R. H. K. Foster and coworkers71 have studied piperidine derivatives with 
morpholine like analgesia activity. Study of (2S)-1-(arylacetyl)-2-
N
N
N
N
NHO
FF
(12)
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(aminomethyl)piperidine derivatives and highly selective kappa opioid analgesics was 
given by V. Vecchietti et al.72 M. Eiichi and coworkers73 have synthesized and reported 
antiallergic activity of novel pyrazine derivative. Synthesis and anti mycobacterial 
evaluation of some pyrazine-2-carboxylic acid hydrazide derivatives was documented by 
A. A. Mohamed et al.74 G. Katarzyna et al.75 have synthesized and screened antibacterial 
activity of novel pyrazine derivative obtained from amindoximes. Synthesis and 
antibacterial activity of 6-methoxypyrazine-2-carboxylic acid hydrazide derivatives was 
reported by G. Katarzyna et al.76 Synthesis and antimicrobial activity of 2,3-(substituted 
phenyl)pyrazine dicarboxamide was given by N. S. Rao et al.77 Pyrazine-2-substituted 
carboxamide derivatives synthesis, antimicrobial and leuconostoc mesenteroides growth 
inhibition activity study investigated by A. H. F. Wahab et al.78 N. B. Patel et al.79 have 
synthesized and reported antimicrobial activity of 2-[3-(arylureido)carbonyl]pyrazine 
derivatives. A study of 2-piperidino-1-ethanol and its derivatives as antimicrobial 
additives to oils was reported by S. A. Gamzaeva et al.80  
Looking to the interesting properties of 2-(piperidine-4-ylmethoxy)pyrazine, we 
have synthesized some new 2-(piperidine-4-ylmethoxy)pyrazine, which have been 
describe as under. 
 
 
PART-I: STUDIES ON 2-(PIPERIDINE-4-YLMETHOXY)PYRAZINE 
DERIVATIVES  
 
SECTION-I:  SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL{4-
[({5-[3-(METHYLSULFONYL)PHENYL]PYRAZIN-2-YL}OXY) 
METHYL]PIPERIDIN-1-YL}METHANONES 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-
({[5-(2-FLUOROPHENYL)PYRAZIN-2-YL]OXY}METHYL) 
PIPERIDIN-1-YL]METHANONES 
SECTION-III: SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-
({[5-(THIOPHEN-2-YL)PYRAZIN-2-YL]OXY}METHYL) 
PIPERIDIN-1-YL]METHANONES 
SECTION-IV: SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-
({[5-(1-BENZOTHIOPHEN-3-YL)PYRAZIN-2-YL]OXY} 
METHYL)PIPERIDIN-1-YL]METHANONES    
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL{4-[({5-[3-
(METHYLSULFONYL)PHENYL]PYRAZIN-2-YL}OXY)METHYL]PIPERIDIN-
1-YL}METHANONES 
 
Pyrazine nucleus possesses remarkable pharmaceutical importance and biological 
activities, some of their derivatives occur as natural products. In view of these findings, it 
appeared of interest to synthesize 2-(piperidin-4-ylmethoxy)pyrazines derivatives by the 
condensation of 2-[3-(methylsulfonyl)phenyl]-5-(piperidin-4-ylmethoxy)pyrazine with 
various aromatic acid chlorides in the presence of TEA, as shown in reaction scheme. 
 
REACTION SCHEME 
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The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of 5-Bromopyrazin-2-amine. 
To a stirred cooled to 0 oC solution of 2-aminopyrazine (10.0 g, 0.105 mol) in dry 
DCM (250 ml), N-bromosuccinamide (18.72 g, 0.105 mol) was added portion wise. The 
mixture was stirred at 0 oC for 24 hour. The reaction was monitored on TLC. After 
completion of the reaction, saturated aqueous solution of sodium carbonate was added 
(200 ml) to quench the reaction. The organic layer was washed with brine and dried over 
anhydrous Na2SO4. The solvent was removed in vacuo and the resulting crude product 
was purified by column chromatography on silica gel (eluent: 2 : 8 = E.A. : Hexane) to 
obtain pure product. Yield: 70 %, mp 133-135 oC. 
 
[B] Preparation of 5-Bromopyrazin-2-ol. 
 
Sodium nitrite (8.9 g, 0.129 mol) was added portion wise with stirring to 
concentrated H2SO4 (49 ml) at 0 oC and the mixture was warmed to dissolved the solid. 
The mixture was cooled to 5 oC. To this a solution of 5-bromopyrazin-2-amine (15.0 g, 
0.086 mol) in concentrated H2SO4 (71 ml) was added slowly. The reaction mixture was 
stirred bellow 5 oC for 30 minute and warmed to 40 oC for 2 hour. The reaction mixture 
was poured onto crushed ice. The aqueous solution was extracted with ethyl acetate (250 
ml x 3) and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the 
solid product was obtained. Yield: 50 %, mp 80-82 oC. 
 
[C] Preparation of 5-Bromopyrazin-2-yl methanesulfonate. 
 
To a stirred cooled (ice bath) solution of 5-bromopyrazin-2-ol (5.0 g, 0.028 mol) 
in dry DCM (25 ml), TEA (5.85 ml, 0.042 mol) and CH3SO2Cl (2.80 ml, 0.034 mol) was 
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added dropwise in solution at 0 oC. The reaction mixture was stirred for 2 hour at room 
temperature (monitored by TLC), and the solvent was removed in vacuo. The product 
was filtered, washed with water and dried to give analytical pure product. Yield: 80 %, 
mp 85-87 oC. 
 
[D] Preparation of  tert-Butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate. 
To a stirred suspension of K2CO3 (3.036 g, 0.022 mol) and 5-bromopyrazin-2-yl 
methanesulfonate (3.0 g, 0.011 mol) in dry DMF (30 ml), tert-butyl 4-
(hydroxymethyl)piperidine-1-carboxylate (2.54 g, 0.011 mol) was added. The solution 
was heated on a water bath for 2 hour (monitored by TLC). The reaction mixture was 
poured onto crushed ice, thus the precipitate obtained, was filtered and washed with water 
to give pure product. Yield: 68 %, mp 99-101 oC.  
 
[E] Preparation of tert-Butyl 4-((5-(3-(methylsulfonyl)phenyl)pyrazine-2-
yloxy)methyl)piperidine-1-carboxylate. 
A solution of tert-butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was further stirred for 5.0 minute. To this 
solution 3-(methylsulfonyl)phenylboronic acid (0.66 g, 0.004 mol), isopropylalcohol (20 
ml) was added at room temperature. To this content a solution of K2CO3 (10.0 ml, 0.02 
mol) in water was added dropwise under nitrogen atmosphere and stirred for 5.0 minute. 
Palladium tetrakistriphenylphosphine (0.231 g, 0.0002 mol) was added in to the above 
reaction mixture and the reaction mixture was heated to reflux for 6 hour (monitored by 
TLC). The reaction mixture was added in to the water under stirring. The aqueous layer 
was extracted with ethylacetate (100 ml × 3), and the combined organic layers were 
washed with water followed by brine and dried over anhydrous Na2SO4. The solvent was 
evaporated under vacuum to give crude product. The crude product was used in the next 
step without further purification. 
 
[F] Preparation of 2-[3-(Methylsulfonyl)phenyl]-5-(piperidin-4-ylmethoxy) 
pyrazine. 
A mixture of HCl in dioxane (10 ml) and tert-butyl 4-((5-(3-(methylsulfonyl) 
phenyl)pyrazine-2-yloxy)methyl)piperidine-1-carboxylate was stirred at room 
temperature for overnight (monitored by TLC), and the solvent was removed in vacuo. 
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Water and ethylacetate was added in to the crude product and stirred well. The organic 
layer was separated and the major impurities were removed in the organic layer. The 
aqueous layer was basified using sodium hydroxide solution and the product was 
extracted with DCM (100 ml × 3). The combined organic layers were washed with water 
followed by brine and dried over anhydrous Na2SO4. The solvent was evaporated under 
vacuum to give pure product. Yield: 60 %, mp 138-139 oC.    
 
[G] General procedure for the preparation of Aryl{4-[({5-[3-
(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-yl}methanones. 
To a stirred cooled (ice bath) solution of 2-[3-(methylsulfonyl)phenyl]-5-
(piperidin-4-ylmethoxy)pyrazine (0.2 g, 0.576 mmol) and aryl acid (0.576 mmol) in dry 
DMF (3 ml), HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluoro 
phosphate) (0.262 g, 0.691 mmol) and TEA (0.1 ml, 0.864 mmol)  was added at 0 oC. The 
reaction mixture was stirred for 10 hour at room temperature (monitored by TLC). The 
reaction mixture was poured onto crushed ice, thus the precipitate separated was filtered 
and washed with water to give pure product. The physical constants of the products are 
recorder in Table-1a. 
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Table-1a: Physical constants of Aryl{4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-
yl}oxy)methyl]piperidin-1-yl}methanones. 
 
N
N
O
N
O
R
S
O
O
CH3
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
1a CH3
O  
C25H27N3O4S 
 
465.56 
 
75 0.53 
1b 
O
CH3
 
 
C25H27N3O4S 
 
465.56 69 0.51 
1c N
O  
 
C23H24N4O4S 
 
 
452.52 
 
72 0.42 
1d 
N
O  
 
C23H24N4O4S 
 
 
452.52 
 
65 0.40 
1e 
O
OCH3  
C25H27N3O5S 
 
 
481.56 
 
77 0.45 
1f 
O  
C25H27N3O4S 
 
 
465.56 
 
82 0.47 
1g O
NH
O
CH3
 
C26H28N4O5S 
 
 
508.58 
 
62 0.30 
1h 
O Br 
 
C25H26BrN3O4S 
 
 
544.46 
 
75 0.39 
1i 
O
NH2
Br
 
C24H25BrN4O4S 
 
545.44 
 
66 0.35 
 
1j 
 O
Cl
 
 
C24H24ClN3O4S 
 
 
485.98 
 
 
80 0.41 
            TLC solvent system:- E.A. : Hexane = 6 : 4 
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ANALYTICAL DATA 
(4-Methylphenyl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-
1-yl}methanone (1a). mp 160-162 oC; IR (KBr): 3001, 2929, 2846, 1622, 1538, 1461, 
1341, 1301, 1149, 1015, 827 cm-1; MS: m/z = 365 [M]+; Anal. Calcd for C25H27N3O4S: C, 
64.50; H, 5.85; N, 9.03. Found: C, 64.23; H, 5.76; N, 8.95%. 
 
(2-Methylphenyl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-
1-yl}methanone (1b). mp 182-184 oC; Purity by HPLC: 89 %; IR (KBr): 3007 (Ar, C-H 
str), 2923 (C-H str), 2860 (C-H str), 1627 (amide, C=O str), 1537 (Ar, C=C str), 1463 
(Ar, C=C str), 1344 (C-H ban), 1301 (S=O str asym), 1150 (S=O str sym), 1095 (C-N 
str), 1010 (C-O-C str), 742 (C-H o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 
1.40-1.47 (m, 2H, 2CH), 1.75-1.78 (d, J=12.64 Hz, 1H, CH), 1.98-2.02 (d, J=13.08 Hz, 
1H, CH), 2.11-2.17 (m, 1H, CH), 2.29 (s, 3H, CH3), 2.83-2.97 (m, 1H, CH), 2.98-3.05 
(m, 1H, CH), 3.09 (s, 3H, CH3), 3.54-3.57 (d, J=12.40 Hz, 1H, CH), 4.27-4.28 (d, J=6.40 
Hz, 2H, CH2), 4.87-4.90 (d, J=12.92 Hz, 1H, CH), 7.21-7.30 (m, 4H, ArH), 8.02-8.05 (m, 
2H, ArH), 8.21-8.14 (m, 2H, ArH), 8.31 (s, 1H, ArH), 8.56-8.57 (d, J=1.24 Hz 1H, ArH). 
13C NMR (100 MHz, CDCl3): δ ppm 19.70, 30.10, 35.46, 42.10, 44.59, 46.19, 70.16, 
120.18, 123.51, 126.84, 128.08, 130.94, 135.78, 138.14, 140.62, 144.29, 152.55, 156.16, 
159.28, 170.21; MS: m/z = 366 [M+1]+; Anal. Calcd for C25H27N3O4S: C, 64.50; H, 5.85; 
N, 9.03. Found: C, 64.19; H, 5.77; N, 8.93%. 
 
(Pyridin-4-yl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-
yl}methanone (1c). mp 233-235oC; IR (KBr): 3001, 2916, 2869, 1617, 1535, 1449, 1339, 
1300, 1148, 1010, 750 cm-1; MS: m/z = 353 [M+1]+; Anal. Calcd for C23H24N4O4S: C, 
62.70; H, 5.61; N, 10.27. Found: C, 62.50; H, 5.52; N, 10.15%. 
 
(Pyridin-2-yl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-
yl}methanone (1d). mp 219-221 oC; Purity by HPLC: 92 %; IR (KBr): 3003, 2919, 2867, 
1616, 1534, 1463, 1340, 1300, 1148, 1089, 1058 cm-1; 1H NMR (400 MHz, CDCl3): δ 
ppm 1.45-1.54 (m, 2H, 2CH), 1.82-1.85 (d, J=12.56 Hz, 1H, CH), 1.98-2.01 (d, J=12.88 
Hz, 1H, CH), 2.17-2.18 (m, J=13.48 Hz, 1H, CH), 4.28-4.29 (d, J=6.52 Hz, 2H, CH2), 
4.81-4.84 (d, J=13.12 Hz, 1H, CH), 7.33-7.36 (m, 1H, ArH), 7.61-7.63 (d, J=7.76 Hz, 
1H, ArH), 7.78-7.82 (m, 1H, ArH), 8.02-8.05 (m, 2H, ArH), 8.11-8.14 (m, 2H, ArH), 
8.32-8.33 (d, J=1.28 Hz, 1H, ArH), 8.56-8.57 (d, J=1.4 Hz, 1H, ArH), 8.59-8.60 (d, J=4.2 
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Hz, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 28.10, 35.92, 42.25, 44.59, 46.17, 
70.61, 120.08, 123.61, 126.83, 128.07, 131.74, 135.43, 137.10, 138.16, 140.23, 144.16, 
152.15, 156.64, 159.94, 170.94; MS: m/z = 453 [M+1]+; Anal. Calcd for C23H24N4O4S: C, 
61.05; H, 5.35; N, 12.38. Found: C, 60.89; H, 5.26; N, 12.25%. 
 
(3-Methoxyphenyl)[{4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2yl}oxy)methyl] 
piperidin-1-yl}methanone (1e). mp 173-175 oC; IR (KBr): 3148, 2921, 2861, 1627, 1538, 
1460, 1344, 1301, 1150, 1010, 739 cm-1; MS: m/z = 481 [M]+; Anal. Calcd for 
C25H27N3O5S: C, 62.71; H, 5.68; N, 9.62. Found: C, 62.48; H, 5.62; N, 9.49%. 
 
1-{4-[({5-[3-(Methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-yl}-2-
phenylethanone (1f). mp 149-151 oC; IR (KBr): 3001, 2929, 2846, 1622, 1538, 1461, 
1341, 1301, 1149, 1015, 755 cm-1; MS: m/z = 465 [M]+; Anal. Calcd for C25H27N3O4S: C, 
64.50; H, 5.85; N, 9.03. Found: C, 64.20; H, 5.80; N, 8.90%. 
 
(N-Phenylacetamide){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl] 
piperidin-1-yl}methanone (1g). mp 238-240 oC; IR (KBr): 3345, 3015, 2918, 2823, 1610, 
1545, 1445, 1355, 1290, 1115, 1020, 825 cm-1; MS: m/z = 508 [M]+; Anal. Calcd for 
C26H28N4O5S: C, 61.40; H, 5.55; N, 11.02. Found: C, 61.19; H, 5.45; N, 10.91%. 
[4-(Bromomethyl)phenyl]{4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl] 
piperidin-1-yl}methanone (1h). mp 167-168 oC; IR (KBr): 3023, 2950, 2826, 1595, 1512, 
1442, 1332, 1290, 1140, 1032, 840, 612 cm-1; MS: m/z = 555 [M+1]+; Anal. Calcd for 
C25H26BrN3O4S: C, 55.64; H, 4.80; N, 8.89. Found: C, 55.44; H, 4.72; N, 8.76%. 
(2-Amino-5-bromophenyl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl] 
piperidin-1-yl}methanone (1i). mp 190-192 oC; IR (KBr): 3456, 3385, 3037, 2948, 2852, 
1610, 1545, 1462, 1322, 1334, 1152, 1028, 620 cm-1; MS: m/z = 546 [M+1]+; Anal. Calcd 
for C24H25BrN4O4S: C, 52.85; H, 4.62; N, 10.27. Found: C, 52.62; H, 4.57; N, 10.20%.  
(4-Chlorophenyl){4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy)methyl]piperidin-
1-yl}methanone (1j). mp 145-147 oC; IR (KBr): 3045, 2941, 2853, 1620, 1541, 1440, 
1311, 1260, 1153, 1015, 820, 740 cm-1; MS: m/z = 486 [M+1]+; Anal. Calcd for 
C24H24ClN3O4S: C, 59.31; H, 4.98; N, 8.65. Found: C, 59.04; H, 4.90; N, 8.52%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 1b 
 
 
IR spectra of compound 1d
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Mass spectrum of compound 1b 
 
 
Mass spectrum of compound 1d 
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1H NMR spectrum of compound 1b 
 
 
Expanded spectrum of compound 1b 
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Expanded spectrum of compound 1b 
 
 
1H NMR spectrum of compound 1d 
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Expanded spectrum of compound 1d 
 
 
Expanded spectrum of compound 1d 
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13C NMR spectrum of compound 1d 
 
 
13C NMR spectrum of compound 1d 
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HPLC of compound 1b 
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HPLC of compound 1d 
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ANTIMICROBIAL ACTIVITY 
Biological evaluation of Aryl{4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-yl}oxy) 
methyl]piperidin-1-yl}methanones. 
All of the synthesized compounds (1a-j) were tested for their antibacterial and 
antifungal activity (MIC) in vitro by broth dilution method38-40 with two Gram-positive 
bacteria Staphylococcus aureus MTCC-96 and Streptococcus pyogenes MTCC 442, two 
Gram-negative bacteria Escherichia coli MTCC 443 and Pseudomonas aeruginosa 
MTCC 1688 and three fungal strains Candida albicans MTCC 227, Aspergillus Niger 
MTCC 282 and Aspergillus clavatus MTCC 1323 taking gentamycin, ampicillin, 
chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs. 
The standard strains were procured from the Microbial Type Culture Collection (MTCC), 
Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly synthesized 
compounds, defined as the lowest concentration of the compound preventing the visible 
growth, were determined by using micro dilution broth method according to NCCLS 
standards.38 
 
Minimal Inhibition Concentration [MIC] 
The main advantage of the Broth Dilution Method for MIC determination lies in 
the fact that it can readily be converted to determine the MIC as well. 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately subcultured (before 
inoculation) by spreading a loopful evenly over a quarter of plate of medium 
suitable for the growth of the test organism and put for incubation at 37 0C 
overnight.  
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation (which represents 
the original inoculums) is compared.  
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Methods used for primary and secondary screening 
Each synthesized compounds was diluted obtaining 2000 μg mL-1 concentration, 
as a stock solution. Inoculum size for test strain was adjusted to 108 cfu (colony forming 
unit) per milliliter by comparing the turbidity. 
 
Primary screen: In primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 
concentrations of the synthesized compounds were taken. The active synthesized drugs 
found in this primary screening were further tested in a second set of dilution against all 
microorganisms.  
 
Secondary screen: The compounds found active in primary screening were similarly 
diluted to obtain 200 μg mL-1, 100 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 
6.250 μg mL-1 concentrations.  
 
Reading Result: The highest dilution showing at least 99 % inhibition zone is taken as 
MIC. The result of this is much affected by the size of the inoculums. The test mixture 
should contain 108 organism/mL.     
 
                The results obtained from antimicrobial susceptibility testing are depicted in 
Table 1b. 
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Table-1b: Antimicrobial activity of Aryl{4-[({5-[3-(methylsulfonyl)phenyl]pyrazin-2-         
       yl}oxy)methyl]piperidin-1-yl}methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1a 200 200 200 250 1000 500 500 
1b 250 250 62.5 100 1000 >1000 >1000 
1c 500 500 250 250 1000 500 500 
1d 500 250 200 125 500 >1000 >1000 
1e 62.5 100 250 500 500 500 1000 
1f 200 125 100 250 1000 1000 500 
1g 125 500 500 200 >1000 1000 1000 
1h 250 250 100 100 >1000 >1000 500 
1i 200 200 200 125 500 500 >1000 
1j 500 200 100 500 1000 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
 
 
 
 
 
 
 
 
 
Studies on heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                         50 
SECTION-II 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-({[5-(2-
FLUOROPHENYL)PYRAZIN-2-YL]OXY}METHYL)PIPERIDIN-1-YL] 
METHANONES 
 
Many pyrazine derivatives have displayed diverse pharmacological activities. In 
view of our on going interest in the synthesis of some new 2-(piperidin-4-
ylmethoxy)pyrazine derivatives we have under taken the synthesis of 2-(2-fluorophenyl)-
5-(piperidin-4-ylmethoxy)pyrazine with various aromatic acid chlorides in the presence 
of TEA. 
 
REACTION SCHEME 
Pd(PPh3)4, K2CO3 
   
B
OH
OH
F
toluene, IPA
N
N
O
N
O
O
F
N
N
O
N
O
Br O +
deprotection  HCl in dioxane 
N
N
O
NH
F
HBTU, Et3N, DMF
R-COOH
N
N
O
N
O
R
F  
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of  tert-Butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-Butyl 4-((5-(2-fluorophenyl)pyrazine-2-yloxy)methyl) 
piperidine-1-carboxylate. 
A solution of tert-butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minute. To this 
solution 2-fluorophenylboronic acid (0.56 g, 0.004 mol) and isopropyl alcohol (20 ml) 
was added at room temperature. To this content a solution of K2CO3 (10 ml, 0.02 mol) in 
water was added dropwise under nitrogen atmosphere and stirred for 5.0 minute. 
Palladium tetrakistriphenylphosphine (0.231 g, 0.0002 mol) was added in to the above 
reaction mixture and the reaction mixture was heated to reflux for 6 hour (monitored by 
TLC). The reaction mixture was added in to the water under stirring. The aqueous layer 
was extracted with ethylacetate (100 ml × 3), and the combined organic layers were 
washed with water followed by brine and dried over anhydrous Na2SO4. The solvent was 
evaporated under vacuum to give crude product. The crude product was used in the next 
step without further purification. 
 
[C] Preparation of 2-[2-Fluorophenyl]-5-(piperidin-4-ylmethoxy)pyrazine. 
A mixture of HCl in dioxane (10 ml) and tert-butyl 4-((5-(2-fluorophenyl) 
pyrazine-2-yloxy)methyl)piperidine-1-carboxylate was stirred at room temperature for 
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overnight (monitored by TLC), and the solvent was removed in vacuo. Water and 
ethylacetate was added in to the crude product and stirred well. The organic layer was 
separated and the major impurities were removed in the organic layer. The aqueous layer 
was basified using sodium hydroxide solution and the product was extracted with DCM 
(100 ml × 3). The combined organic layers were washed with water followed by brine 
and dried over anhydrous Na2SO4. The solvent was evaporated under vacuum to give 
pure product. Yield: 63 %, mp 141-143 oC.    
 
[D] General procedure for the preparation of Aryl{4-[({5-[2-
fluorophenyl]pyrazin-2-yl}oxy)methyl]piperidin-1-yl}methanones. 
To a stirred cooled (ice bath) solution of 2-[2-fluorophenyl]-5-(piperidin-4-
ylmethoxy)pyrazine (0.2 g, 0.696 mmol) and aryl acid (0.696 mmol) in dry DMF (3 ml), 
HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate) 
(0.316 g, 0.835 mmol) and TEA (0.1 ml, 0.835 mmol)  was added at 0 oC. The reaction 
mixture was stirred for 10 hour at room temperature (monitored by TLC). The reaction 
mixture was poured onto crushed ice, thus the precipitate separated was filtered and 
washed with water to give pure product. The physical constants of the products are 
recorder in Table-2a. 
 
[E] Biological evaluation of Aryl[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl) 
 piperidin-1-yl]methanones.  
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-2b. 
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Table-2a: Physical constants of Aryl[4-({[5-(2-fluorophenyl)pyrazin-2- 
yl]oxy}methyl)piperidin-1-yl]methanones. 
 
N
N
O
N
O
R
F  
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
2a CH3
O  
 
C24H24FN3O2 
 
 
405.46 
 
80 0.51 
2b 
O
CH3
 
 
C24H24FN3O2 
 
 
405.46 
 
68 0.49 
2c N
O  
 
C22H21FN4O2 
 
392.42 75 0.43 
2d 
N
O  
 
C22H21FN4O2 
 
 
392.42 
 
71 0.42 
2e 
O
OCH3  
C24H24FN3O3 
 
421.46 79 0.46 
2f 
O  
C24H24FN3O2 
 
 
405.46 
 
85 0.48 
2g O
NH
O
CH3
 
C25H25FN4O3 
 
 
448.48 
 
60 0.28 
2h 
O Br 
 
C24H23BrFN3O2 
 
484.36 74 0.36 
2i 
O
NH2
Br
 
C23H22BrFN4O2 
 
 
485.34 
 
61 0.30 
 
2j 
 O
Cl
 
 
C23H21ClFN3O2 
 
 
425.88 
 
78 0.46 
            TLC solvent system:- E.A. : Hexane = 5 : 5 
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ANALYTICAL DATA 
(4-Methylphenyl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2a). mp 148-150 oC; Purity by HPLC: 93 %; IR (KBr): 3060 (Ar, C-H str), 
2877 (C-H str), 2850 (C-H str), 1636 (amide, C=O str), 1534 (Ar, C=C str), 1464 (Ar, 
C=C str), 1338 (C-H ban), 1167 (str C-F), 1051 (C-N str), 1006 (C-O-C str), 840 (C-H 
o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 1.24-1.30 (m, 2H, 2CH), 1.81-1.88 
(m, 2H, 2CH), 2.09-2.14 (m, 1H, CH), 2.38 (s, 3H, CH3), 2.85-3.15 (m, 2H, 2CH), 3.86-
3.88 (d, J=13.24 Hz, 1H, CH), 4.24-4.25 (d, J=6.48 Hz, 2H, CH2), 4.76-4.78 (d, J=13.4 
Hz, 1H, CH), 7.13-7.16 (m, 2H, ArH), 7.17-7.21 (m, 2H, ArH), 7.28-7.36 (m, 2H, ArH), 
7.86-7.91 (m, 2H, ArH), 8.26-8.27 (d, J=1.4 Hz, 1H, ArH), 8.44-8.45 (d, J=1.4 Hz, 1H, 
ArH). 13C NMR (100 MHz, CDCl3): δ ppm 21.40, 30.44, 36.02, 42.71, 47.16, 70.35, 
115.81, 116.02, 127.02, 127.91, 129.07, 132.72, 133.23, 134.71, 137.10, 139.87, 144.50, 
155.23, 159.33; MS: m/z = 405 [M]+; Anal. Calcd for C24H24FN3O2: C, 71.09; H, 5.97; N, 
10.36. Found: C, 70.80; H, 5.90; N, 10.21%. 
 
(2-Methylphenyl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2b). mp 128-130 oC; IR (KBr): 3045, 2923, 2860, 1624, 1537, 1464, 1340, 
1169, 1055, 1010, 832 cm-1; MS: m/z = 405 [M]+; Anal. Calcd for C24H24FN3O2: C, 
71.09; H, 5.97; N, 10.36. Found: C, 70.82; H, 5.92; N, 10.22%. 
 
(Pyridin-4-yl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2c). mp 120-122 oC; IR (KBr): 3010, 2960, 2837, 1642, 1558, 1440, 1330, 
1123, 1066, 1015, 746 cm-1; MS: m/z = 392 [M]+; Anal. Calcd for C22H21FN4O2: C, 
67.33; H, 5.39; N, 14.28. Found: C, 67.08; H, 5.30; N, 14.15%. 
 
(Pyridin-2-yl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2d). mp 100-101 oC; IR (KBr): 3017, 2925, 2850, 1610, 1532, 1461, 1328, 
1136, 1068, 1017, 740 cm-1; MS: m/z = 392 [M]+; Anal. Calcd for C22H21FN4O2: C, 
67.33; H, 5.39; N, 14.28. Found: C, 67.01; H, 5.32; N, 14.19%. 
 
(3-Methoxyphenyl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2e). mp 90-91 oC; Purity by HPLC: 95 %; IR (KBr): 3063, 2924, 2858, 
1627, 1537, 1478, 1340, 1166, 1050, 1012, 750 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 
1.25-1.50 (m, 2H, 2CH), 1.84-1.96 (m, 2H, 2CH), 2.14-2.17 (m, 1H, CH), 2.83-2.89 (m, 
1H, CH), 3.02-3.07 (m, 1H, CH), 3.82-3.86 (m, 4H, OCH3,CH), 4.24-4.26 (d, J=6.4 Hz, 
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2H, CH2), 4.76-4.79 (d, J=13.0 Hz, 1H, CH), 6.94-6.95 (m, 3H, ArH), 7.13-7.19 (m, 2H, 
ArH), 7.29-7.36 (m, 1H, ArH), 7.86-7.90 (m, 2H, ArH), 8.26-8.27 (d, J=1.36 Hz, 1H, 
ArH), 8.44-8.45 (d, J=1.32 Hz, 1H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 29.32, 
34.71, 42.50, 45.77, 54.70, 70.16, 115.72, 115.96, 127.10, 127.80, 129.10, 132.66, 
133.33, 134.61, 137.17, 139.89, 144.33, 155.44, 159.30; MS: m/z = 421 [M]+; Anal. 
Calcd for C24H24FN3O3: C, 68.74; H, 5.77; N, 10.98. Found: C, 68.53; H, 5.70; N, 
10.88%. 
 
1-[4-({[5-(2-Fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]-2-phenylethanone 
(2f). mp 97-99 oC; IR (KBr): 3032, 2960, 2860, 1641, 1525, 1470, 1342, 1162, 1010, 823 
cm-1; MS: m/z = 405 [M]+; Anal. Calcd for C24H24FN3O2: C, 71.09; H, 5.97; N, 10.36. 
Found: C, 70.85; H, 5.90; N, 10.28%. 
 
(N-Phenylacetamide)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2g). mp 162-164 oC; IR (KBr): 3360, 3027, 2956, 2826, 1617, 1536, 1465, 
1323, 1163, 1036, 1001, 838 cm-1; MS: m/z = 448 [M]+; Anal. Calcd for C25H25FN4O3: C, 
66.95; H, 5.62; N, 12.49. Found: C, 66.73; H, 5.57; N, 12.40%. 
 
[4-(Bromomethyl)phenyl][4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-
yl]methanone (2h). mp 141-142 oC; IR (KBr): 3027, 2956, 2826, 1617, 1536, 1465, 
1323, 1153, 1056, 1022, 838, 615 cm-1; MS: m/z = 485 [M+1]+; Anal. Calcd for 
C24H23BrFN3O2: C, 59.51; H, 4.79; N, 8.68. Found: C, 59.18; H, 4.70; N, 8.55%. 
 
(2-Amino-5-bromophenyl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-
yl]methanone (2i). mp 155-157 oC; IR (KBr): 3433, 3350, 3020, 2940, 2843, 1616, 1542, 
1450, 1330, 1160, 1018, 631 cm-1; MS: m/z = 486 [M+1]+; Anal. Calcd for 
C23H22BrFN4O2: C, 56.92; H, 4.57; N, 11.54. Found: C, 56.69; H, 4.52; N, 11.43%. 
 
(4-Chlorophenyl)[4-({[5-(2-fluorophenyl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (2j). mp 102-104 oC; IR (KBr): 30256, 2929, 2860, 1629, 1554, 1460, 1321, 
1170, 1040, 1003, 818 cm-1; MS: m/z = 426 [M+1]+; Anal. Calcd for C23H21ClFN3O2: C, 
64.86; H, 4.97; N, 9.87. Found: C, 64.60; H, 4.93; N, 9.78%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 2a 
 
 
IR spectra of compound 2e 
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Mass spectrum of compound 2a 
 
 
Mass spectrum of compound 2e 
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1H NMR spectrum of compound 2a 
 
 
Expanded spectrum of compound 2a 
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1H NMR spectrum of compound 2e 
 
 
Expanded spectrum of compound 2e 
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Expanded spectrum of compound 2e 
 
 
13C NMR spectrum of compound 2a 
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13C NMR spectrum of compound 2e 
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HPLC of compound 2a 
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HPLC of compound 2e 
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Table-2b: Antimicrobial activity of Aryl[4-({[5-(2-fluorophenyl)pyrazin-2-     
       yl]oxy}methyl)piperidin-1-yl]methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
2a 200 200 200 250 1000 1000 1000 
2b 125 100 100 62.5 250 500 250 
2c 250 100 500 500 500 1000 1000 
2d 62.5 125 500 500 250 >1000 >1000 
2e 100 100 250 250 500 1000 1000 
2f 500 250 500 200 250 500 250 
2g 125 200 250 250 500 250 500 
2h 250 250 200 500 >1000 500 250 
2i 500 500 250 200 500 1000 500 
2j 100 62.5 125 100 500 >1000 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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SECTION-III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-({[5-(THIOPHEN-
2-YL)PYRAZIN-2-YL]OXY}METHYL)PIPERIDIN-1-YL]METHANONES 
 
Pyrazine derivatives have been attracted widespread attention due to their diverse 
pharmacological properties.  Looking to this, the synthesis of 2-(piperidin-4-
ylmethoxy)pyrazines derivatives have been under taken by the condensation of 2-
(piperidin-4-ylmethoxy)-5-(thiophen-2-yl)pyrazines with various aromatic acid chlorides 
in the presence of TEA. 
 
REACTION SCHEME 
 
Pd(PPh3)4, K2CO3 
   
toluene, IPA
N
N
O
N
O
Br O +
deprotection HCl in dioxane 
HBTU, Et3N, DMF
R-COOH
S
B
OH
OH N
N
O
N
O
O
S
N
N
O
NH
S
N
N
O
N
O
R
S
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of  tert-Butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-Butyl 4-((5-(thiophen-2-yl)pyrazine-2-yloxy)methyl) 
piperidine-1-carboxylate. 
A solution of tert-butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minute. To this 
solution thiophen-2-yl-2-boronic acid (0.51 g, 0.004 mol) and isopropylalcohol (20 ml) 
was added at room temperature. To this content a solution of K2CO3 (10 ml, 0.02 mol) in 
water was added dropwise under nitrogen atmosphere and stirred for 5.0 minute. 
Palladium tetrakistriphenylphosphine (0.231 g, 0.0002 mol) was added in to the above 
reaction mixture and the reaction mixture was heated to reflux for 7 hour (monitored by 
TLC). The reaction mixture was added in to the water under stirring. The aqueous layer 
was extracted with ethylacetate (100 ml × 3), and the combined organic layers were 
washed with water followed by brine and dried over anhydrous Na2SO4. The solvent was 
evaporated under vacuum to give crude product. The crude product was used in the next 
step without further purification. 
 
[C] Preparation of 2-[Thiophen-2-yl]-5-(piperidin-4-ylmethoxy)pyrazine. 
A mixture of HCl in dioxane (10 ml) and tert-butyl 4-((5-(thiophen-2-yl)pyrazine-
2-yloxy)methyl)piperidine-1-carboxylate was stirred at room temperature for overnight 
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(monitored by TLC), and the solvent was removed in vacuo. Water and ethylacetate was 
added in to the crude product and stirred well. The organic layer was separated and the 
major impurities were removed in the organic layer. The aqueous layer was basified using 
sodium hydroxide solution and the product was extracted with DCM (100 ml × 3), and 
the combine organic layers were washed with water followed by brine and dried over 
anhydrous Na2SO4. The solvent was evaporated under vacuum to give pure product. 
Yield: 58 %, mp 88-90 oC.    
 
[D] General procedure for the preparation of Aryl{4-[({5-[thiophen-2-yl]pyrazin-
2-yl}oxy)methyl]piperidin-1-yl}methanones. 
To a stirred cooled (ice bath) solution of 2-[thiophen-2-yl]-5-(piperidin-4-
ylmethoxy)pyrazine (0.2 g, 0.727 mmol) and aryl acid (0.727 mmol) in dry DMF (3 ml), 
HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate) 
(0.330 g, 0.872 mmol) and TEA (0.14 ml, 1.018 mmol)  was added at 0 oC. The reaction 
mixture was stirred for 10 hour at room temperature (monitored by TLC). The reaction 
mixture was poured onto crushed ice, thus the precipitate separated was filtered and 
washed with water to give pure product. The physical constants of the products are 
recorder in Table-3a. 
 
[E] Biological evaluation of Aryl[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl) 
 piperidin-1-yl]methanones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-3b. 
 
 
 
 
 
 
 
 
Studies on heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                         68 
Table-3a: Physical constants of Aryl[4-({[5-(thiophen-2-yl)pyrazin-2-
yl]oxy}methyl)piperidin-1-yl]methanones. 
 
N
N
O
N
O
R
S  
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
3a CH3
O  
 
C22H23N3O2S 
 
 
393.50 
 
78 0.50 
3b 
O
CH3
 
C22H23N3O2S 
 
393.50 
 
84 0.48 
3c N
O  
 
C20H20N4O2S 
 
380.46 65 0.39 
3d 
N
O  
 
C20H20N4O2S 
 
 
380.46 
 
67 0.37 
3e 
O
OCH3  
C22H23N3O3S 
 
 
409.50 
 
70 0.43 
3f 
O  
C22H23N3O2S 
 
 
393.50 
 
60 0.46 
3g O
NH
O
CH3
 
C23H24N4O3S 
 
436.52 64 0.30 
3h 
O Br 
 
C22H22BrN3O2S 
 
472.39 75 0.42 
3i 
O
NH2
Br
C21H21BrN4O2S 
 
473.38 
 
77 0.34 
 
3j 
 O
Cl
 
 
C21H20ClN3O2S 
 
 
413.92 
 
70 0.45 
             TLC solvent system:- MeOH : CHCl3 = 1 : 9 
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ANALYTICAL DATA 
(4-Methylphenyl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3a). mp 82-84 oC; IR (KBr): 3032, 2941, 2863, 1636, 1521, 1453, 1339, 
1158, 1012, 842 cm-1; MS: m/z = 394 [M+1]+; Anal. Calcd for C22H23N3O2S: C, 67.15; 
H, 5.89; N, 10.68. Found: C, 66.91; H, 5.82; N, 10.58%. 
 
(2-Methylphenyl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3b). mp 93-95 oC; IR (KBr): 3038, 2940, 2853, 1628, 1525, 1450, 1329, 
1175, 1017, 740 cm-1; MS: m/z = 393 [M]+; Anal. Calcd for C22H23N3O2S: C, 67.15; H, 
5.89; N, 10.68. Found: C, 66.88; H, 5.84; N, 10.59%. 
 
(Pyridin-4-yl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]methanone 
(3c). mp 160-162 oC; IR (KBr): 3010, 2925, 28558, 1627, 1545, 1468, 1316, 1170, 1033, 
720 cm-1; MS: m/z = 381 [M+1]+; Anal. Calcd for C20H20N4O2S: C, 63.14; H, 5.30; N, 
14.73. Found: C, 62.97; H, 5.25; N, 14.61%. 
 
(Pyridin-2-yl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]methanone 
(3d). mp 140-142 oC; IR (KBr): 3031, 2958, 2891, 1620, 1542, 1478, 1298, 1150, 1031, 
721 cm-1; MS: m/z = 381 [M+1]+; Anal. Calcd for C20H20N4O2S: C, 63.14; H, 5.30; N, 
14.73. Found: C, 62.94; H, 5.26; N, 14.63%. 
 
(3-Methoxyphenyl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3e). mp 102-104 oC; IR (KBr): 3023, 2930, 2861, 1616, 1541, 1460, 1299, 
1131, 1016, 760 cm-1; MS: m/z = 409 [M]+; Anal. Calcd for C22H23N3O3S: C, 64.53; H, 
5.66; N, 10.26. Found: C, 64.20; H, 5.59; N, 10.14%. 
 
1-[4-({[5-(Thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]-2-phenylethanone 
(3f). mp 95-97 oC; IR (KBr): 3042, 2935, 2860, 1610, 1564, 1488, 1320, 1112, 1007, 737 
cm-1; MS: m/z = 393 [M]+; Anal. Calcd for C22H23N3O2S: C, 67.15; H, 5.89; N, 10.68. 
Found: C, 66.85; H, 5.81; N, 10.60%. 
 
(N-Phenylacetamide)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3g). mp 198-200 oC; Purity by HPLC: 90 %; IR (KBr): 3243 (N-H str), 3027 
(Ar, C-H str), 2907 (C-H str), 2853 (C-H str), 1688 (amide, C=O str), 1611 (N-H ban), 
1523 (Ar, C=C str), 1447 (Ar, C=C str), 1330 (C-H ban), 1166 (C-N str), 1015 (C-O-C 
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str), 863 (C-H o.p. ban) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 1.25-1.49 (m, 2H, 
2CH), 1.83-1.93 (m, 2H, 2CH), 2.11-2.17 (m, 1H, CH), 2.19 (s, 3H, COCH3), 2.80-2.88 
(m, 1H, CH), 2.92-3.01 (m, 1H, CH), 3.92-3.95 (d, J=12.48 Hz, 1H, CH), 4.17-4.19 (d, 
J=6.4 Hz, 2H, CH), 4.71-4.74 (d, J=12.20 Hz, 1H, CH), 7.41-7.43 (m, 3H, ArH), 7.57-
7.58 (m, 3H, ArH), 7.79-7.80 (m, 1H, ArH), 8.01-8.02 (d, J=1.28 Hz, 1H, ArH), 8.16-
8.17 (d, J=1.28 Hz, 1H, ArH), 8.22 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 
24.77, 30.23, 34.29, 41.78, 46.12, 70.36, 115.12, 118.81, 126.21, 127.26, 128.58, 129.66, 
132.19, 134.44, 135.38, 137.32, 141.47, 159.18, 165.95, 169.15; MS: m/z = 436 [M]+; 
Anal. Calcd for C23H24N4O3S: C, 63.28; H, 5.54; N, 12.83. Found: C, 63.02; H, 5.49; N, 
12.73%. 
 
[4-(Bromomethyl)phenyl][4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3h). mp 87-89 oC; IR (KBr): 3038, 2940, 2853, 1618, 1525, 1450, 1329, 
1175, 1017, 840, 635 cm-1; MS: m/z = 473 [M+1]+; Anal. Calcd for C22H22BrN3O2S: C, 
55.93; H, 4.69; N, 8.90. Found: C, 55.80; H, 4.61; N, 8.78%. 
 
(2-Amino-5-bromophenyl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-
yl]methanone (3i). mp 135-136 oC; Purity by HPLC: 87 %; IR (KBr): 3483, 3390, 3013, 
2943, 2856, 1638, 1609, 1535, 1443, 1329, 1162, 1017, 651 cm-1; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.25-1.40 (m, 2H, 2CH), 1.91-1.94 (m, 1H, CH), 2.11-2.14 (m, 1H, CH), 
2.49-2.54 (m, 1H, CH), 2.94-2.97 (m, 1H, CH), 3.30-3.37 (m, 1H, CH), 3.68-3.71 (d, 
J=12.48 Hz, 1H, CH), 4.23-4.24 (d, J=6.52 Hz, 2H, CH2), 4.54-4.57 (d, J=12.84 Hz, 1H, 
CH), 5.30 (s, 2H, NH2), 6.67-6.69 (d, J=8.52 Hz, 1H, ArH), 7.20-7.21 (m, 2H, ArH), 
7.41-7.43 (m, 1H, ArH), 7.57-7.58 (m, 1H, ArH), 7.79-7.80 (m, 1H, ArH), 8.01-8.02 (d, 
J=1.24 Hz, 1H, ArH), 8.16-8.17 (d, J=1.20 Hz, 1H, ArH). 13C NMR (100 MHz, CDCl3): 
δ ppm 30.47, 35.79, 41.70, 46.11, 70.42, 115.17, 120.23, 126.01, 127.23, 128.54, 129.12, 
132.30, 134.11, 135.42, 137.78, 141.17, 144.38, 151.41, 159.52, 167.68; MS: m/z = 473 
[M]+; Anal. Calcd for C21H21BrN4O2S: C, 53.28; H, 4.47; N, 11.84. Found: C, 52.99; H, 
4.40; N, 11.72%. 
 
(4-Chlorophenyl)[4-({[5-(thiophen-2-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (3j). mp 120-121 oC; IR (KBr): 3023, 2943, 2851, 1622, 1510, 1442, 1346, 
1165, 1037, 836, 840 cm-1; MS: m/z = 414 [M+1]+; Anal. Calcd for C21H20ClN3O2S: C, 
60.94; H, 4.87; N, 10.15. Found: C, 60.69; H, 4.83; N, 10.02%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 3g 
 
 
IR spectra of compound 3i 
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Mass spectrum of compound 3g 
 
 
Mass spectrum of compound 3i 
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1H NMR spectrum of compound 3g 
 
 
Expanded spectrum of compound 3g 
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Expanded spectrum of compound 3g 
 
 
1H NMR spectrum of compound 3i 
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Expanded spectrum of compound 3i 
 
 
Expanded spectrum of compound 3i 
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13C NMR spectrum of compound 3g 
 
 
13C NMR spectrum of compound 3i 
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HPLC of compound 3g 
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HPLC of compound 3i 
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Table-3b: Antimicrobial activity of Aryl[4-({[5-(thiophen-2-yl)pyrazin-2-  
       yl]oxy}methyl)piperidin-1-yl]methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
3a 100 200 200 250 >1000 500 200 
3b 62.5 100 125 100 1000 >1000 500 
3c 250 250 62.5 100 500 250 200 
3d 200 100 125 62.5 200 500 250 
3e 125 100 62.5 200 250 200 500 
3f 100 62.5 250 250 200 250 500 
3g 100 100 100 125 200 >1000 >1000 
3h 200 125 250 250 250 1000 1000 
3i 250 200 250 200 1000 1000 1000 
3j 200 250 125 250 500 250 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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SECTION-IV 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ARYL[4-({[5-(1-
BENZOTHIOPHEN-3-YL)PYRAZIN-2-YL]OXY}METHYL)PIPERIDIN-1-
YL]METHANONES 
 
Pyrazine play an important role as intermediates for perfumes, pharmaceuticals, 
agricultural chemicals and food spices. In view of these reports, we have synthesize 2-
(piperidin-4-ylmethoxy)pyrazines derivatives by the condensation of 2-(1-benzothiophen-
3-yl)-5-(piperidin-4-ylmethoxy)pyrazines with various aromatic acid chlorides in the 
presence of TEA. 
 
REACTION SCHEME 
 
Pd(PPh3)4, K2CO3 
   
toluene, IPA
N
N
O
N
O
Br O +
deprotection HCl in dioxane 
HBTU, Et3N, DMF
R-COOH
S
B OH
OH
N
N
O
N
O
O
S
N
N
O
NH
S
N
N
O
N
O
R
S
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of  tert-Butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate. 
See, Part-A, Part-1, Section-I Experimental Section [D]. 
 
[B] Preparation of tert-Butyl 4-((5-(1-benzothiophen-3-yl)pyrazine-2-
yloxy)methyl) piperidine-1-carboxylate. 
A solution of tert-butyl 4-{[(5-bromopyrazin-2-yl)oxy]methyl}piperidine-1-
carboxylate (1.5 g, 0.004 mol) in toluene (20 ml) was stirred at room temperature under 
nitrogen atmosphere. The obtained solution was stirred for further 5.0 minute. To this 
solution 1-benzothiophen-3-yl-3-boronic acid (0.712 g, 0.004 mol) and isopropylalcohol 
(20 ml) was added at room temperature. To this content a solution of K2CO3 (10 ml, 0.02 
mol) in water was added dropwise under nitrogen atmosphere and stirred for 5.0 minute. 
Palladium tetrakistriphenylphosphine (0.231 g, 0.0002 mol) was added in to the above 
reaction mixture and the reaction mixture was heated to reflux for 5 hour (monitored by 
TLC). The reaction mixture was added in to the water under stirring. The aqueous layer 
was extracted with ethylacetate (100 ml × 3), and the combined organic layers were 
washed with water followed by brine and dried over anhydrous Na2SO4. The solvent was 
evaporated under vacuum to give crude product. The crude product was used in the next 
step without further purification. 
 
[C] Preparation of 2-[1-Benzothiophen-3-yl]-5-(piperidin-4-ylmethoxy)pyrazine. 
A mixture of HCl in dioxane (10 ml) and tert-butyl 4-((5-(1-benzothiophen-3-
yl)pyrazine-2-yloxy)methyl)piperidine-1-carboxylate was stirred at room temperature for 
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overnight (monitored by TLC), and the solvent was removed in vacuo. Water and 
ethylacetate was added in to the crude product and stirred well. The organic layer was 
separated and the major impurities were removed in the organic layer. The aqueous layer 
was basified using sodium hydroxide solution and the product was extracted with DCM 
(100 ml × 3). The combine organic layers were washed with water followed by brine and 
dried over anhydrous Na2SO4. The solvent was evaporated under vacuum to give pure 
product. Yield: 65 %, mp 81-82 oC.    
 
[D] General procedure for the preparation of Aryl{4-[({5-[1-benzothiophen-3-
yl]pyrazin-2-yl}oxy)methyl]piperidin-1-yl}methanones. 
To a stirred cooled (ice bath) solution of 2-[1-benzothiophen-3-yl]-5-(piperidin-4-
ylmethoxy)pyrazine (0.2 g, 0.615 mmol) and aryl acid (0.615 mmol) in dry DMF (3 ml), 
HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate) 
(0.279 g, 0.738 mmol) and TEA (0.12 ml, 0.922 mmol)  was added at 0 oC. The reaction 
mixture was stirred for 10 hour at room temperature (monitored by TLC). The reaction 
mixture was poured onto crushed ice, thus the precipitate separated was filtered and 
washed with water to give pure product. The physical constants of the products are 
recorder in Table-4a. 
 
[E] Biological evaluation of Aryl[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy} 
 methyl)piperidin-1-yl]methanones.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-4b. 
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Table-4a: Physical constants of Aryl[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-
yl]oxy}methyl)piperidin-1-yl]methanones. 
 
S
N
N
O
N
O
R
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
4a CH3
O  
 
C26H25N3O2S 
 
 
443.56 
 
72 0.52 
4b 
O
CH3
 
C26H25N3O2S 
 
443.56 
 
70 0.51 
4c N
O  
 
C24H22N4O2S 
 
430.52 74 0.46 
4d 
N
O  
 
C24H22N4O2S 
 
 
430.52 
 
66 0.43 
4e 
O
OCH3
C26H25N3O3S 
 
459.56 
 
80 0.45 
4f 
O  
C26H25N3O2S 
 
 
443.56 
 
59 0.48 
4g O
NH
O
CH3
 
C27H26N4O3S 
 
 
486.58 
 
 
62 
 
0.32 
4h 
O Br 
 
C26H24BrN3O2S 
 
522.45 67 0.41 
4i 
O
NH2
Br
 
C25H23BrN4O2S 
 
523.44 78 0.35 
 
4j 
 O
Cl
 
 
C25H22ClN3O2S 
 
 
463.97 
 
84 0.46 
            TLC solvent system:- MeOH : CHCl3 = 2 : 8 
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ANALYTICAL DATA 
(4-Methylphenyl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (4a). mp 108-110 oC; IR (KBr): 3039, 2933, 2858, 1618, 1531, 1444, 1329, 
1176, 1016, 854, cm-1; MS: m/z = 443 [M]+; Anal. Calcd for C26H25N3O2S: C, 70.40; H, 
5.68; N, 9.47. Found: C, 70.11; H, 5.61; N, 9.38%. 
 
(2-Methylphenyl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (4b). mp 99-101 oC; IR (KBr): 3053, 2943, 2843, 1634, 1533, 1444, 1327, 
1180, 1010, 737 cm-1; MS: m/z = 443 [M]+; Anal. Calcd for C26H25N3O2S: C, 70.40; H, 
5.68; N, 9.47. Found: C, 70.09; H, 5.60; N, 9.36% 
 
(Pyridin-4-yl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (4c). mp 80-81 oC; Purity by HPLC: 89 %; IR (KBr): 2993 (Ar, C-H str), 
2943 (C-H str), 2854 (C-H str), 1688 (amide, C=O str), 1533 (Ar, C=C str), 1465 (Ar, 
C=C str), 1336 (C-H ban), 1174 (C-N str), 1008 (C-O-C str), 746 (C-H o.p. ban) cm-1; 1H 
NMR (400 MHz, CDCl3): δ ppm 1.25-1.31 (m, 1H, CH), 1.42-1.48 (m, 1H, CH), 1.81-
1.85 (d, J=12.72 Hz, 1H, CH), 1.96-1.99 (d, J=13.24 Hz, 1H, CH), 2.09-2.17 (m, 1H, 
CH), 2.82-2.88 (t, J=11.32 Hz, 1H, CH), 3.63-3.65 (d, J=9.72 Hz, 1H, CH), 4.19-4.21 
(dd, J=2.12 & 6.36 Hz, 2H, CH2), 4.76-4.79 (d, J=12.48 Hz, 1H, CH), 7.36-7.45 (m, 3H, 
ArH), 7.76-7.84 (m, 2H, ArH), 8.01-8.02 (d, J=1.20 Hz, 1H, ArH), 8.16-8.17 (d, J=1.32 
Hz, 1H, ArH), 8.68-8.73 (m, 2H, ArH). 13C NMR (100 MHz, CDCl3): δ ppm 29.47, 
35.74, 42.42, 47.28, 70.48, 118.20, 120.95, 123.30, 124.62, 128.61, 130.20, 135.32, 
142.81, 144.30, 148.82, 152.74, 155.64, 159.19, 169.15; MS: m/z = 430 [M]+; Anal. 
Calcd for C24H22N4O2S: C, 66.96; H, 5.15; N, 13.01. Found: C, 66.80; H, 5.10; N, 
12.92%. 
 
(Pyridin-2-yl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (4d). mp 86-87 oC; Purity by HPLC: 88 %; IR (KBr): 3001, 2933, 2908, 
1626, 1533, 1465, 1344, 1172, 1010, 748 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm 1.25-
1.33 (m, 1H, CH), 1.39-1.53 (m, 1H, CH), 1.77-1.80 (d, J=12.96 Hz, 1H, CH), 1.93-1.97 
(d, J=13.52 Hz, 1H, CH), 2.08-2.16 (m, 1H, CH), 2.82-2.89 (m, 1H, CH), 3.09-3.16 (m, 
1H, CH), 3.94-3.98 (d, J=13.28 Hz, 1H, CH), 4.18-4.20 (d, J=6.48 Hz, 2H, CH2), 4.78-
4.82 (d, J=13.20 Hz,  1H, CH), 7.36-7.39 (m, 3H, ArH), 7.44-7.48 (m, 1H, ArH), 7.62-
7.69 (m, 1H, ArH), 7.81-7.85 (m, 3H, ArH), 8.01-8.02 (d, J=1.32 Hz, 1H, ArH), 8.16-
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8.17 (d, J=1.32 Hz, 1H, ArH), 8.60-8.61 (d, J=4.36 Hz, 1H, ArH). 13C NMR (100 MHz, 
CDCl3): δ ppm 29.42, 35.80, 42.23, 47.06, 70.81, 114.67, 118.11, 120.54, 123.74, 124.51, 
128.64, 130.20, 132.18, 135.38, 137.54, 142.80, 148.05, 154.15, 159.51, 168.20; MS: m/z 
= 430 [M+1]+; Anal. Calcd for C24H22N4O2S: C, 66.96; H, 5.15; N, 13.01. Found: C, 
66.69; H, 5.12; N, 12.90%. 
 
(3-Methoxyphenyl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-
yl]methanone (4e). mp 92-94 oC; IR (KBr): 3064, 2924, 2879, 1627, 1556, 1527, 1440, 
1327, 1166, 1014, 727 cm-1; MS: m/z = 459 [M]+; Anal. Calcd for C26H25N3O2S: C, 
67.95; H, 5.48; N, 9.14. Found: C, 67.66; H, 5.40; N, 9.04%. 
 
1-[4-({[5-(1-Benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl]-2-
phenylethanone (4f). mp 76-78 oC; IR (KBr): 3015, 2938, 2871, 1636, 1548, 1421, 1314, 
1151, 1018, 736 cm-1; MS: m/z = 443 [M]+; Anal. Calcd for C26H25N3O2S: C, 70.40; H, 
5.68; N, 9.47. Found: C, 70.16; H, 5.63; N, 9.37%. 
 
(N-Phenylacetamide)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-
1-yl]methanone (4g). mp 117-119 oC; IR (KBr): 3347, 3032, 2946, 2821, 1628, 1556, 
1443, 1331, 1224, 1157, 1032, 842 cm-1; MS: m/z = 486 [M]+; Anal. Calcd for 
C27H26N4O3S: C, 66.65; H, 5.39; N, 11.51. Found: C, 66.35; H, 5.30; N, 11.04%. 
 
[4-(Bromomethyl)phenyl][4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl) 
piperidin-1-yl]methanone (4h). mp 72-74 oC; IR (KBr): 3048, 2951, 2820, 1636, 1530, 
1455, 1323, 1112, 1041, 824, 621 cm-1; MS: m/z = 523 [M+1]+; Anal. Calcd for 
C26H24BrN3O2S: C, 59.77; H, 4.63; N, 8.04. Found: C, 59.49; H, 4.59; N, 7.90%. 
 
(2-Amino-5-bromophenyl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl) 
piperidin-1-yl]methanone (4i). mp 120-121 oC; IR (KBr): 3433, 3350, 3020, 2940, 2843, 
1616, 1542, 1450, 1320, 1330, 1116, 1018, 631 cm-1; MS: m/z = 524 [M+1]+; Anal. 
Calcd for C25H23BrN4O2S: C, 57.36; H, 4.43; N, 10.70. Found: C, 57.02; H, 4.39; N, 
10.59%. 
 
(4-Chlorophenyl)[4-({[5-(1-benzothiophen-3-yl)pyrazin-2-yl]oxy}methyl)piperidin-1-yl] 
methanone (4j). mp 112-114 oC; IR (KBr): 3033, 2910, 2830, 1629, 1515, 1443, 1334, 
1241, 1118, 1019, 821, 670 cm-1; MS: m/z = 465 [M+1]+; Anal. Calcd for 
C25H22ClN3O2S: C, 64.72; H, 4.78; N, 9.06. Found: C, 64.50; H, 4.70; N, 8.59%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 4c 
 
 
IR spectra of compound 4d 
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Mass spectrum of compound 4d 
 
 
1H NMR spectrum of compound 4c 
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Expanded spectrum of compound 4c 
 
 
Expanded spectrum of compound 4c 
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1H NMR spectrum of compound 4d 
 
 
Expanded spectrum of compound 4d 
 
N
NS
O
N
O
N
Studies on heterocyclic… 
2-(Piperidin-4-ylmethoxy)pyrazine derivatives…                                                                         90 
Expanded spectrum of compound 4d 
 
 
13C NMR spectrum of compound 4c 
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13C NMR spectrum of compound 4d 
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HPLC of compound 4c 
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HPLC of compound 4d 
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Table-4b: Antimicrobial activity of Aryl[4-({[5-(1-benzothiophen-3-yl)pyrazin-2- 
       yl]oxy}methyl)piperidin-1-yl]methanones. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
4a 100 200 250 500 200 250 500 
4b 200 200 250 250 250 1000 1000 
4c 500 500 200 62.5 >1000 >1000 >1000 
4d 100 125 100 100 >1000 >1000 500 
4e 100 250 100 500 500 1000 500 
4f 62.5 100 125 100 250 200 200 
4g 200 100 125 200 1000 1000 1000 
4h 500 250 250 200 500 500 1000 
4i 100 125 62.5 100 250 1000 200 
4j 250 500 500 250 1000 250 250 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
Indole (2,3-benzopyrrole, ketole, 1-benzazole; C8H7N) is an aromatic heterocyclic 
organic compound. It has a bicyclic structure, consisting of a six-membered benzene ring 
fused to a five-membered nitrogen-containing pyrrole ring. The participation of the 
nitrogen lone pair electron in the aromatic ring means that indole is not a base, and it does 
not behave like a simple amine.  
Indole is a solid at room temperature. It can be produced by bacteria as a 
degradation product of the amino acid tryptophan. It occurs naturally in human faces and 
has an intense facial odor. At very low concentrations, however, it has a flowery smell, 
and is a constituent of many flower scents (such as orange blossoms) and perfumes. It 
also occurs in coal tar. 
 
N
H
1
2
34
5
6
7
(1)  
 
Indole compounds include the plant hormone Auxin (indolyl-3-acetic acid), the 
anti-inflammatory drug indomethacin, the betablocker pindolol, and the naturally 
occurring hallucinogen dimethyltryptamine. 
The name indole is a portmanteau of the words indigo and oleum, since indole 
was first isolated by treatment of the indigo dye with oleum. Indole chemistry began to 
develop with the study of the dye indigo. Indigo can be converted to isatin and then to 
oxindole. Then, in 1866, Adolf von Baeyer reduced oxindole to indole using zinc dust.1 In 
1869, he proposed a formula for indole.2  
Certain indole derivatives were important dyestuffs until the end of the 19th 
century. In the 1930, interest in indole intensified when it became known that the indole 
nucleus is present in many important alkaloids, as well is in tryptophan and auxins, and it 
remains an active area of research today.3 
The indole skeleton is one of the most attractive frameworks with a wide range of 
biological and pharmacological activities.4 This physiologically important nucleus is 
abundantly found in therapeutic agents5,6 as well as in natural products. Many researchers 
have described synthesis of indole and its derivatives along with its applications in 
literature.7 
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SYNTHETIC ASPECT 
Various methods for the preparation of indole derivatives have been cited in 
literature, some of them are as under. 
1. B. George8 has reported one-pot microwave assisted synthesis of indole from 
phenylhydrazine and pyruvic acid. 
 
NH
NH2 O
HOOC
CH3
ZnCl2
PCl5 N
H
+
 
 
2. N. Sakai et al.9 have synthesized indium-catalyzed cyclization of 2-ethynylanilines 
produced various indole derivatives in good yields for substrates having an alkyl 
or aryl group on the terminal alkyne. 
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3
R
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R
2
5 mol -% in Br3
toluene, reflux 5-20 h
R
1
N
R
3
R
2
 
 
3. Rhodium (II) perfluorobutyrate-mediated decomposition of vinyl azides 
allows rapid access to a variety of complexes of indole was prepared by B. 
J. Stokes et al.10 
 
N3
O
O
CH3
R
1 R
1
N
H
O CH3
O
3-5 mol-% 
toluene, 60 oC, 16 h
Rh2(OCOC3F7)4
 
 
4. Y. Du and coworkers11 have been synthesized various N-arylated and N-alkylated 
indoles and pyrrole-fused aromatic compounds by a phenyliodine 
bis(trifluoroacetate) (PIFA)-mediated intramolecular cyclization. 
 
R
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R
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1.3 eq. PhI(O2CCF3)2(PIFA)
CH2Cl2, RT, 30 min
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5. Microwave-assisted synthesis of indole derivatives in water via 
cycloisomerization of 2-alkynylanilines and alkynylpyridinamines promoted by A. 
Carpita et al.12,13 
 
NH2
R
2
R
1 H2O, 200 
oC
MW, base/acid salt
R
1
N
H
R
2
 
 
6. Synthesis of 2-substituted indoles via palladium-catalyzed domino Heck reaction 
with 71 % yield was given by H. Mao et al.14 
 
I
N R
1 N
H
R
1Pd(OAc)2, PPh3, 120
oC
KOBu-t, DMSO
 
 
7. D. K. Whelligan and coworkers15 have synthesized two-step aza- and diazaindoles 
from chloroamino-N-heterocycles using ethoxyvinylborolane. 
 
NH2
OEt
R
1 AcOH
R
1
N
H  
 
8. One-pot synthesis of indole derivatives from nitroarenes under hydrogenation 
condition with supported gold nanoparticles was reported by Y. Yamane et al.16 
 
NO2
R
1
N
H
R
1H2
Au/Fe2O3
 
 
9. A mild preparation of substituted indole from simple aromatic precursors using 
(trimethylsilyl)diazomethane was reported by L. Zhu et al.17 
 
 
N
HNH2
O
TMSCHN2, CS2CO3
MeOH, 60oC
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10. E. V. Sadanandan et al.18 have synthesized 4,6,7-trimethoxyindol marine 
alkaloids. 
 
OMe
OMe
MeO
COOMe
N3
xylene
reflux
OMe
OMe
MeO N
H
COOMe
 
 
11. S. Wagaw et al.19 have reported novel fischer indole synthesis.  
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12. G. A. Kraus and coworkers20 have synthesized indole derivatives under 
microwave-assisted conditions with high yields in one-pot reaction. 
 
+
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13. Gold(III)-catalyzed indole derivatives from 2-alkynylanilines in EtOH annulations 
at room temperature in good yields was reported by A. Arcadi et al.21   
 
R
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N
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14. Copper(II)-catalyzed cyclization of 2-ethynylaniline derivatives to indoles can be 
carried out in a MeOH was given by K. Hiroya et al.22 
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15. A. Dobbs et al.23 have synthesized indole derivatives from ortho-
bromonitrobenzenes with various vinyl grignard reagents in THF.  
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16. One-pot synthesis of indoles by a palladium-catalyzed annulation of ortho-
iodoanilines and aldehydes under mild ligandless conditions in DMF was reported 
by Y. Jia et al.24  
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17. Suzuki-Miyaura coupling of ortho-gem-dihalovinylanilines with boronic acids, of 
a Pd(OAc)2 catalyst in the presence of K3PO4·H2O was doccumented by Y. Q. 
Fang et al.25 
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N
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R
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18. V. Sridharan et al.26 have synthesized microwave assisted 2-arylindoles in good 
yields. 
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19. Lewis acids catalyzed cyclization of methyl phenyldiazoacetates was reported by 
L. Zhou et al.27  
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REACTION MECHANISM 
 The reaction of phenyl hydrazine with an aldehyde or ketone initially forms 
phenylhydrazone which isomerizes to the respective enamine. After protonation, a cyclic 
sigmatropic rearrangement occurs producing an imine. The resulting imine forms a cyclic 
aminoacetal, which under acid catalysis eliminates NH3, resulting in the energetically 
favorable aromatic indole. 
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+
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H
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Phenylhydrazone Enamine Imine
AminoacetalIndole  
 
  
THERAPEUTIC IMPORTANCE 
The indole ring system represents a privileged structure in drug discovery. The 
number of bioactive compounds containing this ring system is so vast that the complete 
range of their biological activities can be hardly classified.28-30 
1. Analgesic31 
2. Antiallergic32 
3. Antibacterial33 
4. Anticonvulsant34 
5. Antifungal35 
6. Antihistaminic36 
7. Anti-inflammatory37 
8. Antitumor38 
Studies on heterocyclic… 
Indole derivatives…                         105 
9. Antiviral39 
10. β-adrenergic40 
11. Diuretic41 
12. Insecticidal42 
13. Anticancer43 
14. Anti HIV44 
15. Anti hypertensive45 
16. Cardiovascular46 
17. Antioxidant47 
 
B. Pelcman et al.48 have synthesized marine sponge pigment fascaplysin (2) from 
indole and reported their antimicrobial activity.  
 
N
H
N
(2)  
 
M. C. Pirrung et al.49 have synthesized indolylquinones (3) and checked their 
activity on the human insulin receptor by demethylasterriquinone B1 (DAQ B1) and its 
consequent oral insulin mimetic activity tested in mice by B. Zhang and coworkers.50 
DAQ B1 was also subsequently shown to activate the TrkA nerve growth factor receptor 
was reported by N. Wilkie and coworkers.51 
 
O
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H
N
H
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OH
(3)  
 
Activities of asterriquinones (4) against HIV protease and HIV reverse 
transcriptase have been disclosed by A. Fredenhagen et al.52 and K. Ono et al.53 and also 
activity against serine proteases given by U. Mocek et al.54 
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(4)  
S. Pasquini et al.55 prepared library of 1,5-disubstituted-3-indole-N-
alkylacetamides as CB2 receptor ligands. Some representatives of CB2 agonists are 
compounds AM1241, GW405833, JWH-015 and AM630 possess an indole structure 
reported by K. Mackie et al.56 and C. Manera et al.57  
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J. B. Blair et al.58 have synthesized fluorinated indole (5) derivatives.  
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R
2
R
3
R
4
R1 = OH, H, F  R2 = H, OCH3
R3 = H, F   R4 = H, F
(5)
 
 
P. Diana et al.59 have synthesized 3,5-bis(3’-indolyl)pyrazoles (6) by cyclization 
of diketones and hydrazine monohydrate and evaluated their antitumor properties. The 
interest in this class of compounds has been stimulated by both their unique chemical 
structure and the wide range of biological properties including antiviral, antimicrobial, 
and antitumor activity was given by V. M. Dembitsky et al.60 
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H. Sard et al.61 have synthesized psilocybin analogs (7) and discoved a selective 
5-HT2C agonist. 
 
N
H
O
R N
R = H, P(O)(OH)2
(7)  
 
E. J. Glamkowski et al.62 have synthesized 3-(4-acylaminopiperazin-1-
ylalky1)indoles (8) as potential anti hypertensive agents. 
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H
N
N
NH
R
1
O
R1 = aryl
(8)  
 
M. Banerjee et al.63 have synthesized indole derivatives, such as HIV-1 
nonnucleoside reverse transcriptase inhibitor. D. C. Cole et al.64 have tested 5-HT 
receptor agonists or antagonists. Q. Shi et al.65 and H. D. H. Showalter et al.66 have 
synthesized and tested peroxisome proliferator-activated receptor (PPAR) agonists and 
protein tyrosine kinase inhibitors. G. Primofiore and coworkers67 and K. L. Lee et al.68 
have prepared and tested benzodiazepine receptor (BzR) ligands. Human cytosolic 
phospholipase A2R inhibitor and blood coagulation factor Xa inhibitor have also been 
presented by H. Matter et al.69 
J. Holenz et al.70 prepared medicinal chemistry driven approaches toward novel 
and selective serotonin 5-HT6 receptor ligands (9). 
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Preparation and antibacterial activities of indole containg compounds reported by 
Y. Yasuo et al.71 T. Bhawana et al.72 have synthesized and tested antimicrobial activity 
of indole derivatives. Synthesis and biological screening of some new indole 
derivatives doccumented by D. S. Mehta et al.73 and G. S. Gadaginamath et al.74 Potent 
antimicrobial activity of indole derivatives against methicillin-resistant Staphylococcus 
aureus investigated by  R. A. Al-Qawasmeh et al.75 Regioselective synthesis and 
biological evaluation of bis(indolyl)methane derivatives as anti-infective agents given 
by M. Damodiran et al.76 
Discovery of indole inhibitor of cytosolis phospholipase A2α reported by K. L. 
Lee et al.77 Y. Kawashima et al.78 have studied structure activity of indole derivatives 
with analgesic and anti-inflammatory activities. Synthesis and anti-inflammatory 
activity of heterocyclic indole derivatives reported by R. Preeti et al.79 Amido indole 
derivatives used in cannabinoid receptor modulators discovered by H. John et al.80 
M. G. Bursavich et al.81 have synthesized indole derivatives and tested for PI3 
kinase-α and the mammalian target. Synthesis and evaluation of indole derivatives as 
antagonists of Wnt/β-catenin, signaling and CLL cell survival reported by J. Guangyi 
et al.82   D. A. James and coworkers83 synthesized conjugated indole-imidazole 
derivatives, displaying cytotoxicity against multidrug resistant cancer cell lines. C. 
Girolamo et al.84 have synthesized derivatives of the new ring system indole with 
potent antitumor and antimicrobial activity. B. Emile et al.85 have synthesized 
substituted indole derivatives as new class of antineoplastics agent. 
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Endogenous substances and marketed drugs with indole substructures 
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Thus the important role displayed by indole and its derivatives for various 
therapeutic and biological activities prompted us to synthesize some carboxylate, and  
glyoxylamide derivatives bearing indole moiety in order to achieve compounds having 
better therapeutic activities described as in the following parts. 
 
 
STUDIES ON 6-CHLORO-INDOLE DERIVATIVES 
 
PART-I: STUDIES ON 6-CHLORO-INDOLE-5-CARBOXYLATE 
DERIVATIVES  
PART-II: STUDIES ON 6-CHLORO-INDOLE-3-YL-GLYOXYLAMIDE 
DERIVATIVES 
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INTRODUCTION     
Indole-3-yl-glyoxylamide derivatives are potent biologically active agent has led 
to the exploration of large number of structural variants, containing 6-chloro-indole-5-
carboxylate moiety as an invariable ingredient so the synthesis of these compounds has 
become an important target in current years. The diversity, efficiency and rapid access to 
small and highly functionalized organic molecules makes this approach of central current 
interest in the construction of compounds library and optimization in drug discovery 
process.1,2  
 
N
H
O
O
N R
2R
1
(1)  
 
A new class of indole-3-yl-glyoxylamide derivatives is high affinity agonists at 
the benzodiazepine binding site receptors. It has proved a rich source of clinically 
effective drugs, particularly anxiolytics, hypnotics and anticonvulsants. 
 
SYNTHETIC ASPECT 
Various methods for the preparation of 3-oxoacetamide-1H-indole derivatives and 
alkylation of indole have been cited in literature, some of the methods are as under. 
 
ALKYLATION  
1. K. T. Potts et al.3 have synthesized 1-methylindole from indole, CH3I and NaNH2 in 
diethyl ether solution.  
N
H
CH3I
NaNH2, Et2O N
CH3 
 
2. R. S. Davidson et al.4 have reported N-alkylation of indole using phase transfer 
catalyst with ultrasound. 
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N
H
N
C6H5CH2Br
PEG methyl ether
 
 
3. Potassium carbonate as a base for the N-alkylation of indole in ionic liquid was 
prepared by Y. R. Jorapur et al.5 
 
N
H
+ Br Ph
[bmim][BF4], CH3CN
K2CO3, 110 
oC N
Ph  
 
4. Alkylation of indole from potassium hydroxide, alkyl/aryl halide in acetone was 
reported by C. A. Marlic et al.6   
 
N
H
N
R
1
KOH, R1X
acetone
 
 
5. Synthesis of N-alkyl substituted indole in presence of sodium hydride in DMF was 
documented by S. Roy et al. 7 
 
N
H
N
NC
NaH, DMF
Br CN
 
 
6. Dual nucleophilic catalysis with DABCO for the N-methylation of indoles was 
synthesized  by W. Shieh et al.8 
 
N
H
R
1 DABCO, DMF
 MDC, 95 oC N
R
1
CH3 
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7. B. Sebastian et al.9 have synthesized selective Ruthenium-catalyzed N-alkylation of 
indole by using alcohol. 
 
N
H
R
1
+ R
2
OH 24 h, toluene N
R
1
R
2
Shvo, PTSA
 
 
GLYOXYLAMIDE 
8. The use of (NHC)CuI complex in combination with a N-heterocyclic carbene 
precursor as catalyst for the double carbonylation of aryl iodides and secondary 
amines solves the problem of using the precious metal Pd and phosphine ligands 
was reported  by J. Liu et al.10 
 
I
R
1
+ CO + NH
R
2
R
2
NHC-Cu-I
CS2CO3
R
1
O
O
N
R
2
R
2
 
 
9. J. Zhua and coworkers11 have given one-pot synthesis of nitrogen-containing 
heteroaryl α-keto amides from heteroaryl halides.  
 
  
R
1
Cl + N
NC
O R
1
O
O
N(1) Base, THF
(2) CH3COOH
 
 
10. I. Bennacefa et al.12 have synthesized halogenated N,N-dialkylel-(2-phenyl-1H-
indol-3-yl)glyoxylamide derivatives.  
 
N
H
N
H
O
O
R
1
(1) (COCl)2, THF, 0
OC
(2) Amine, THF, 0OC
 
 
11. R. Gitto et al.13 have synthesized glyoxylamide derivatives containing N-substituted 
isoquinoline nucleus. 
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12. One-step synthesis of N-alkyl-2-aryl-2-oxoacetamide derivatives was given by I. 
Yavari et al.14 
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13. M. Takhi et al.15 have synthesized 3-indolylglyoxamide derivatives. 
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secondary amine
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REACTION MECHANISM 
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THERAPEUTIC IMPORTANCE 
6-Chloro-indole-3-yl-glyoxylamide derivatives have been tested for various 
pharmacological activities, which have been summarized as under. 
1. Anticancer16 
2. Antitumor17 
3. Anxiolytic18 
4. Anti-HIV19 
5. Antiviral20 
6. Antimicrobial15 
7. Antileishmanial21 
8. GABA-A receptor22 
9.  Antihypertensive23 
10. Cardiovascular24 
 
F. D. Settimo et al.25 have studied anxiolytic effects of N,N-dialkyl-2-phenylindol-
3-ylglyoxylamides (2) by modulation of translocator protein promoting neurosteroid 
biosynthesis. M. Gavish et al.26 and P. Casellas et al.27 have synthesized indole-3- 
glyoxamide derivatives in a variety of biological processes, including calcium 
homeostasis, lipid metabolism, mitochondrial oxidation, cell growth and differentiation, 
apoptosis induction, and regulation of immune functions. G. Primofiore et al.28 have 
synthesized N,N-dialkyl-2-phenylindol-3-ylglyoxylamides a new class of potent and 
selective ligands at the peripheral benzodiazepine receptor. 
 
N
H
N R
2R
1
R
3
O
OR
4
R
5
R1 = R2 = (CH2)2CH3
R3 = NO2, CF3, H, F
R4 = H, NO2, OCH3, F, Cl
R5 = H, Cl, CH3
(2)  
 
N. A. Meanwell et al.29 have described the discovery of indole-3-glyoxamide (3) 
derivatives as the first small molecule inhibitors of the gp120-CD4 interaction (HIV-1 
attachment inhibition) that demonstrate potent antiviral activity in cell culture.30 
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Antibacterial activities of 3-indolylglyoxamide substituent have been explored in 
an effort to improve the spectrum and potency of this class of agents by M. Takhi et al.15 
 
X
N
O
O
N N
R
1
F
N
O
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R
4R
3R
2
R1 = H, CN, NO2, OCH3, Br
R2 = H, CH3
R3 = H, CH3
  X = CH, N(4)
 
 
A series of marine alkaloid 8,9-dihydrocoscinamide, (5) its analogues and 
indolylglyoxylamide derivatives have been synthesized and screened for their in vitro 
antileishmanial activity profile in promastigote and amastigote models by L. Gupta et al.21 
 
N
O
O
NH
N
R
1
R
2
R
1
 = R
2
 = CH3 = SO2Ph
(5)  
 
I. Collins et al.31 have synthesized new class of N-(indol-3-ylglyoxylyl)piperidines 
(6) are high affinity agonists at the benzodiazepine binding site of human GABA-A 
receptor ion-channels, with modest selectivity for receptors containing the α1. 
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1
R1 = OCH2Ph, NHCH2Ph, N(CH3)CH2Ph
(6)
 
 
G. Primofiore and coworkers32 have synthesized N-(arylalkyl)indol-3-
ylglyoxylylamides (7) targeted as ligands of the benzodiazepine receptor, as well as 
biological evaluation and molecular modeling analysis of the structure activity 
relationships reported by them. 
 
N
H
R
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NH
R
2
R
3
(7)
 
 
 V. W. Pike et al.33 have evaluated novel N-methyl-2-phenylindol-3-
ylglyoxylamides (8) as a new chemo type of 18 kDa translocator protein-selective ligand 
suitable for the development of positron emission tomography radioligands.  
 
N
CH3
NO2
O
O
N
n
Pr
n
Pr
(8)  
 
Preparation of 2-[5-[[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]amino]-1H-
indol-3-yl]-N,N-dimethyl-2-(oxo)acetamide (9) compounds as 5-HT6 receptor modulators 
for use in medicaments was reported by M. V. Ramon et al.34 
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 W. Tao and coworkerss35 have evaluated indole to azaindoles leading to the 
discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-
yl)ethane-1,2-dione as a antiviral activity in HIV-1 infected subjects. J. Wang and 
coworkers36 have modified structure-activity relationship of a small molecule HIV-1 
inhibitor targeting the viral envelope glycoprotein gp120. M. Pascal et al.37 have 
synthesized N-aryl(indol-3-yl)glyoxamides as antitumor agents.  
Literature survey reveals that the compounds bearing glyoxamides moiety possess 
potential drug activity. Looking to the diversified biological activities we have 
synthesized some glyoxamides derivatives in order to achieving better therapeutic agents. 
These studies are described in following section. 
 
 
PART-I: STUDIES ON 6-CHLORO-INDOLE-5-CARBOXYLATE 
DERIVATIVES  
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 6- 
CHLORO-3-[(N,N-DIALKYLAMINO)(OXO)ACETYL]-1-
METHYL-1H-INDOLE-5-CARBOXYLATES.  
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 1-
BENZYL-6-CHLORO-3-[(N,N-DIALKYLAMINO)(OXO)ACETYL]-
1H-INDOLE-5-CARBOXYLATES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 6-CHLORO-3-
[(N,N-DIALKYLAMINO)(OXO)ACETYL]-1-METHYL-1H-INDOLE-5-
CARBOXYLATES  
 
Heterocyclic compounds bearing 6-chloro-indole-5-carboxylate ring system are 
endowed with variety of biological activities. Our strategy is based on to develop a new 
bioactive entity especially with pharmacological activities bearing heterocyclic ring 
system. In view of our on going interest in the synthesis of some new 6-chloro-indole-5-
carboxylate derivatives we have undertaken condensation of methyl 6-chloro-1-methyl-
1H-indole-5-carboxylate with oxalyl chloride and different secondary amine in the 
presence of DCM. 
 
REACTION SCHEME 
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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(I) (COCl)2, dry DCM
(II) Secondary amine N
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R
CH3
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 300 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
 [A] Preparation of Methyl 6-chloro-1-methyl-1H-indole-5-carboxylate. 
To a stirred suspension of CS2CO3 (2.72 g, 0.02 mol) and methyl 6-chloro-1H-
indole-5-carboxylate (2.09 g, 0.01 mol) in dry DMF (10 ml), after 5 minute CH3I (0.62 
ml, 0.01 mol) was added dropwise. The resultant solution was stirred for 5 hour at room 
temperature, and poured onto crushed ice, the product was isolated and washed with 
water and hexane to give pure product. Yield: 95 %, mp 60-61 oC.  
 
[B] General procedure for the preparation of Methyl 6-chloro-3-[(N,N-
dialkylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxylates. 
To a stirred cooled (ice bath) solution of methyl 6-chloro-1-methyl-1H-indole-5-
carboxylate (0.5 g, 2.34 mmol) in dry DCM (12 ml), oxalyl chloride (0.95 ml, 11.21 
mmol) was added dropwise in solution. The obtained solution was stirred at 0 oC for 30.0 
minute and then at 25-30 oC for 1 hour. Dark yellow colored was formed. The solvent 
was removed in vacuo, the residue was dissolved in dry DCM (12 ml) then add different 
secondary amine (6.72 mmol) dropwise. The reaction mixture was stirred at 0 oC for 30.0 
minute and then 25-30 oC for another 30.0 minute (monitored by TLC). The solvent was 
removed in vacuo. The product was dissolved in water and extracted with ethylacetate (25 
ml × 3). The combined organic layers were washed with water followed by brine and 
dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the solid was 
triturated with hexane and resulting precipitate was filtered, washed with hexane and 
dried to give analytical pure product. The physical constants of the product are recorder in 
Table-5a. 
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[C] Biological evaluation of Methyl 6-chloro-3-[(N,N-dialkylamino)(oxo)acetyl]-1-
 methyl-1H-indole-5-carboxylates. 
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-5b. 
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Table-5a: Physical constants of Methyl 6-chloro-3-[(N,N-dialkylamino)(oxo)acetyl]-
1-methyl-1H-indole-5-carboxylates.  
 
 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
5a N
CH3
CH3 
 
C17H19ClN2O4 
 
 
350.79 
 
82 0.41 
5b ON
 
 
C17H17ClN2O5 
 
 
364.78 
 
85 0.35 
5c N
 
 
C18H19ClN2O4 
 
 
362.80 
 
90 0.32 
5d NN CH3
 
 
C18H20ClN3O4 
 
 
377.82 
 
88 0.34 
5e NN
CH3
 
C19H22ClN3O4 
 
 
391.84 
 
80 0.33 
5f NN
 
C23H22ClN3O4 
 
 
439.89 
 
79 0.31 
5g N
CH3
CH3
CH3
CH3  
 
C19H23ClN2O4 
 
 
378.84 
 
81 0.40 
5h N
 
 
C17H17ClN2O4 
 
 
348.78 
 
78 0.38 
5i 
N
CH3  
 
C19H21ClN2O4 
 
376.83 85 0.42 
 
5j 
 
N CH3
 
 
C19H21ClN2O4 
 
 
376.83 
 
84 0.41 
 
               TLC solvent system:- MeoH : CHCl3 = 1 : 9 
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ANALYTICAL DATA 
Methyl 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxylate (5a). 
mp 102-104 oC; Purity by HPLC: 96 %; IR (KBr): 3067 (Ar, C-H str), 2983 (C-H str), 
2943 (C-H str), 1752 (ketone, C=O str), 1633 (amide, C=O str), 1527 (Ar, C=C str), 1466 
(Ar, C=C str), 1365 (C-H ban), 1247 (C-N str), 784 (C-Cl str) cm-1; 1H NMR (300 MHz, 
CDCl3): δ ppm 1.96-1.30 (m, 6H, 2CH3), 3.34-3.41 (q, J=7.04 Hz, 2H, CH2), 3.50-3.57 
(q, J=7.15 Hz, 2H, CH2), 3.84 (s, 3H, CH3), 3.95 (s, 3H, OCH3), 7.45 (s, 1H, ArH), 7.89 
(s, 1H, ArH), 8.84 (s, 1H, ArH). 13C NMR (75 MHz, CDCl3): δ ppm 12.81, 14.47, 33.89, 
39.40, 42.43, 52.37, 112.28, 114.08, 120.57, 124.35, 124.93, 125.98, 129.25, 139.12, 
140.63, 163.26, 166.48, 166.62, 185.17; MS: m/z = 350 [M]+; Anal. Calcd for 
C17H19ClN2O4: C, 58.21; H, 5.46; N, 7.99. Found: C, 57.97; H, 5.40; N, 7.82%.  
 
Methyl 6-chloro-1-methyl-3-[morpholin-4-yl(oxo)acetyl]-1H-indole-5-carboxylate (5b). 
mp 110-112 oC; IR (KBr): 3037, 2948, 2910, 1714, 1635, 1520, 1444, 1258, 787 cm-1; 
MS: m/z = 364 [M]+; Anal. Calcd for C17H17ClN2O5: C, 55.97; H, 4.70; N, 7.68. Found: 
C, 55.65; H, 4.56; N, 7.50%.  
 
Methyl 6-chloro-1-methyl-3-[oxo(piperidin-1-yl)acetyl]-1H-indole-5-carboxylate (5c). 
mp 140-141oC; IR (KBr): 3116, 2979, 2942, 1729, 1708, 1627, 1528, 1442, 1254, 774 
cm-1; MS: m/z = 362 [M]+; Anal. Calcd for C18H19ClN2O4: C, 59.59; H, 5.28; N, 7.72. 
Found: C, 59.22; H, 5.11; N, 7.57%.  
 
Methyl 6-chloro-1-methyl-3-[(4-methylpiperazin-1-yl)(oxo)acetyl]-1H-indole-5-carbox-
ylate (5d). mp 107-109 oC; IR (KBr): 3072, 2975, 2919, 1737, 1629, 1534, 1465, 1236, 
773 cm-1; MS: m/z = 378 [M+1]+; Anal. Calcd for C18H20ClN3O4: C, 57.22; H, 5.34; N, 
11.12. Found: C, 56.90; H, 5.12; N, 10.99%. 
 
Methyl 6-chloro-3-[(4-ethylpiperazin-1-yl)(oxo)acetyl]-1-methyl-1H-indole-5-carboxy- 
late (5e). mp 190-191 oC; IR (KBr): 2974, 2943, 1726, 1636, 1528, 1466, 1240, 771 cm-1; 
MS: m/z = 393 [M+2]+; Anal. Calcd for C19H22ClN3O4: C, 58.24; H, 5.66; N, 10.72. 
Found: C, 57.88; H, 5.53; N, 10.56%. 
 
Methyl 6-chloro-3-[oxo(4-phenylpiperazin-1-yl)acetyl]-1-methyl-1H-indole-5-carboxyl- 
ate (5f). mp 160-161 oC; IR (KBr): 3058, 2980, 2937, 1719, 1633, 1530, 1436, 1251, 763 
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cm-1; MS: m/z = 439 [M]+; Anal. Calcd for C23H22ClN3O4: C, 62.80; H, 5.04; N, 9.55. 
Found: C, 62.50; H, 4.94; N, 9.40%. 
Methyl 6-chloro-3-[(dipropan-2-ylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxyl- 
ate (5g). mp 120-122 oC; Purity by HPLC: 97 %; IR (KBr): 3019, 2972, 2932, 1731, 
1636, 1532, 1470, 1258, 736 cm-1; 1H NMR (300 MHz, CDCl3): δ ppm 1.19-1.21 (d, 
J=6.63 Hz, 6H, 2CH3), 1.56-1.59 (d, J=6.82 Hz, 6H, 2CH3), 3.54-3.64 (m, 1H, CH), 3.85 
(s, 3H, CH3), 3.91 (s, 3H, OCH3), 3.94-4.00 (m, 1H, CH), 7.45 (s, 1H, ArH), 7.80 (s, 1H, 
ArH), 8.82 (s, 1H, ArH). 13C NMR (75 MHz, CDCl3): δ ppm 20.30, 20.79, 33.93, 46.83, 
50.13, 52.33, 112.32, 114.33, 118.39, 122.46, 125.95, 130.02, 139.80, 142.12, 163.85, 
169.51, 191.76; MS: m/z = 378 [M]+; Anal. Calcd for C19H23ClN2O4: C, 60.24; H, 6.12; 
N, 7.39. Found: C, 59.89; H, 6.02; N, 7.25%. 
 
Methyl 6-chloro-1-methyl-3-[oxo(pyrrolidin-1-yl)acetyl]-1H-indole-5-carboxylate (5h). 
mp 165-167 oC; IR (KBr): 3022, 2973, 2927, 1725, 1627, 1521, 1453, 1243, 778 cm-1; 
MS: m/z = 348 [M]+; Anal. Calcd for C17H17ClN2O4: C, 58.54; H, 4.91; N, 8.03. Found: 
C, 58.17; H, 4.72; N, 7.94%. 
 
Methyl 6-chloro-1-methyl-3-[(2-methylpiperidin-1-yl)(oxo)acetyl]-1H-indole-5-carbox-
ylate (5i). mp 170-171 oC; IR (KBr): 3037, 2981, 2944, 1705, 1628, 1528, 1440, 1260, 
774 cm-1; MS: m/z = 377 [M+1]+; Anal. Calcd for C19H23ClN2O4: C, 60.24; H, 6.12; N, 
7.39. Found: C, 59.93; H, 5.98; N, 7.21%. 
 
Methyl 6-chloro-1-methyl-3-[(4-methylpiperidin-1-yl)(oxo)acetyl]-1H-indole-5-carbox-
ylate (5j). mp 173-175 oC; IR (KBr): 3042, 2974, 2940, 1715, 1630, 1525, 1460, 1250, 
752 cm-1; MS: m/z = 377 [M+1]+; Anal. Calcd for C19H21ClN2O4: C, 60.56; H, 5.62; N, 
7.43. Found: C, 60.29; H, 5.37; N, 7.30%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 5a 
 
IR spectra of compound 5g 
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Mass spectrum of compound 5a 
 
 
Mass spectrum of compound 5g 
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 HPLC of compound 5a 
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HPLC of compound 5g 
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Table-5b: Antimicrobial activity of Methyl 6-chloro-3-[(N,N-dialkylamino) 
(oxo)acetyl]-1-methyl-1H-indole-5-carboxylates.  
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
5a 500 500 200 100 1000 500 500 
5b 25 250 200 200 500 1000 1000 
5c 62.5 100 100 100 250 500 250 
5d 100 500 250 500 500 1000 500 
5e 200 200 500 500 250 500 500 
5f 200 250 100 100 500 1000 1000 
5g 500 200 200 250 500 1000 1000 
5h 100 100 62.5 50 250 500 500 
5i 250 500 100 200 1000 500 250 
5j 250 250 100 250 1000 250 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 1-BENZYL-6-
CHLORO-3-[(N,N-DIALKYLAMINO)(OXO)ACETYL]-1H-INDOLE-5-
CARBOXYLATES 
 
Literature survey reveals that nitrogen containing heterocyclic compounds like 6-
chloro-indole-5-carboxylate have received considerable attention in medicinal science 
due to their biological and pharmacological activities. In view of these findings, it 
appeared of interest to synthesize 6-chloro-indole-5-carboxylate derivatives by the 
condensation of methyl 1-benzyl-6-chloro-1H-indole-5-carboxylate with oxalyl chloride 
and different secondary amine in the presence of DCM. 
 
REACTION SCHEME 
 
 
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
 
 
 
 
 
 
N
H
O
O
CH3
Cl
C6H5CH2Cl
CS2CO3, dry DMF
(I) (COCl)2, dry DCM
(II) Secondary amine N
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O
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in CDCl3 solution on a Bruker Ac 300 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
[A] Preparation of Methyl 1-benzyl-6-chloro-1H-indole-5-carboxylate. 
To a stirred suspension of CS2CO3 (2.72 g, 0.02 mol) and methyl 6-chloro-1H-
indole-5-carboxylate (2.09 g, 0.01 mol) in dry DMF (10 ml), after 5.0 minute benzyl 
chloride (1.14 ml, 0.01 mol) was added dropwise. The resultant solution was stirred for 5 
hour at room temperature, and poured onto crushed ice, the product was isolated and 
washed with water and hexane to give pure product. Yield: 94 %, mp 70-72 oC. 
 
[B] General procedure for the preparation of Methyl 1-benzyl-6-chloro-3-[(N,N-
dialkylamino) (oxo)acetyl]-1H-indole-5-carboxylates. 
To a stirred cooled (ice bath) solution of methyl 1-benzyl-6-chloro-1H-indole-5-
carboxylate (0.5 g, 1.67 mmol) in dry DCM (12 ml), oxalyl chloride (0.71 ml, 8.35 mmol) 
was added dropwise in solution. The obtained solution was stirred at 0 oC for 30.0 minute 
and then at 25-30 oC for 1 hour. Dark yellow colored was formed. The solvent was 
removed in vacuo, the residue was dissolved in dry DCM (12 ml) then add different 
secondary amine (5.01 mmol) was added dropwise. The reaction mixture was stirred at 0 
oC for 30.0 minute and then 25-30 oC for another 30.0 minute (monitored by TLC). The 
solvent was removed in vacuo. The product was dissolved in water and extracted with 
ethylacetate (25 ml × 3). The combined organic layers were washed with water followed 
by brine and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the 
solid was triturated with hexane and resulting precipitate was filtered, washed with 
hexane and dried to give analytical pure product. The physical constants of the product 
are recorder in Table-6a. 
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[C] Biological evaluation of Methyl 1-benzyl-6-chloro-3-[(N,N-dialkylamino) 
(oxo)acetyl]-1H-indole-5-carboxylates. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-6b. 
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Table-6a: Physical constants of Methyl 1-benzyl-6-chloro-3-[(N,N-dialkylamino) 
(oxo)acetyl]-1H-indole-5-carboxylates. 
 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
6a N
CH3
CH3 
C23H23ClN2O4 
 
426.89 
 
83 0.51 
6b ON
 
 
C23H21ClN2O5 
 
 
440.87 
 
79 0.42 
6c N
 
 
C24H23ClN2O4 
 
 
438.90 
 
85 0.35 
6d NN CH3
 
 
C24H24ClN3O4 
 
 
453.91 
 
84 0.44 
6e NN
CH3
 
C25H26ClN3O4 
 
 
467.94 
 
86 0.46 
6f NN
 
C25H26ClN3O4 
 
 
467.94 
 
78 0.32 
6g N
CH3
CH3
CH3
CH3  
 
C25H27ClN2O4 
 
454.94 82 0.40 
6h N
 
 
C23H21ClN2O4 
 
 
424.87 
 
84 0.43 
6i 
N
CH3  
 
C25H25ClN2O4 
 
 
452.93 
 
81 0.37 
6j N CH3
 
 
C25H25ClN2O4 
 
 
452.93 
 
82 0.36 
    
                TLC solvent system:- MeoH : CHCl3 = 2 : 8 
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ANALYTICAL DATA 
Methyl 1-benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1H-indole-5-carboxylate (6a). 
mp 78-80 oC; Purity by HPLC: 96 %; IR (KBr): 3038 (Ar, C-H str), 2983 (C-H str), 1725 
(ketone, C=O str), 1629 (amide, C=O str), 1519 (Ar, C=C str), 1447 (Ar, C=C str), 1256 
(C-H ban), 1165 (C-N str), 780 (C-Cl str) cm-1; 1H NMR (300 MHz, CDCl3): δ ppm 1.18-
1.31 (m, 6H, 2CH3), 3.33-3.40 (q, J=6.96 Hz, 2H, CH2), 3.48-3.55 (q, J=7.08 Hz, 2H, 
CH2), 3.95 (s, 3H, OCH3), 5.36 (s, 2H, CH2), 7.13-7.16 (m, 2H, ArH), 7.34-7.38 (m, 4H, 
ArH), 7.95 (s, 1H, ArH), 8.85 (s, 1H, ArH). 13C NMR (75 MHz, CDCl3): δ ppm 12.77, 
14.41, 39.38, 42.46, 51.26, 52.40, 112.79, 114.42, 124.56, 125.09, 125.96, 126.95, 
128.68, 129.26, 134.37, 138.63, 139.92, 163.26, 166.49, 185.31; MS: m/z = 426 [M]+; 
Anal. Calcd for C23H23ClN2O4: C, 64.71; H, 5.43; N, 6.56. Found: C, 64.44; H, 5.29; N, 
6.41%. 
 
Methyl 1-benzyl-6-chloro-3-[morpholin-4-yl(oxo)acetyl]-1H-indole-5-carboxylate (6b). 
mp 98-99 oC; IR (KBr): 3072, 2975, 2926, 1708, 1632, 1547, 1460, 1262, 788 cm-1; MS: 
m/z = 440 [M]+; Anal. Calcd for C23H21ClN2O5: C, 62.66; H, 4.80; N, 6.35. Found: C, 
62.20; H, 4.70; N, 6.22%. 
 
Methyl 1-benzyl-6-chloro-3-[oxo(piperidin-1-yl)acetyl]-1H-indole-5-carboxylate (6c). 
mp 135-137 oC; IR (KBr): 3048, 2968, 2937, 1715, 1645, 1536, 1450, 1278, 756 cm-1; 
MS: m/z = 438 [M]+; Anal. Calcd for C24H23ClN2O4: C, 65.68; H, 5.28; N, 6.38. Found: 
C, 65.26; H, 5.20; N, 6.23%. 
 
Methyl 1-benzyl-6-chloro-3-[(4-methylpiperazin-1-yl)(oxo)acetyl]-1H-indole-5-carboxy-
late (6d). mp 103-105 oC; IR (KBr): 3065, 2945, 2891, 1720, 1635, 1555, 1468, 1246, 
760 cm-1; MS: m/z = 454 [M+1]+; Anal. Calcd for C24H24ClN3O4: C, 63.50; H, 5.33; N, 
9.26. Found: C, 63.05; H, 5.20; N, 9.07%. 
 
Methyl 1-benzyl-6-chloro-3-[(4-ethylpiperazin-1-yl)(oxo)acetyl]-1H-indole-5-carboxyl-
ate (6e). mp 170-171 oC; IR (KBr): 2996, 2975, 2944, 1727, 1635, 1529, 1464, 1240, 771 
cm-1; MS: m/z = 468 [M+1]+; Anal. Calcd for C25H26ClN3O4: C, 64.17; H, 5.60; N, 8.98. 
Found: C, 63.83; H, 5.58; N, 8.79%. 
 
Methyl 1-benzyl-6-chloro-3-[oxo(4-phenylpiperazin-1-yl)acetyl]-1H-indole-5-carboxyl-
ate (6f). mp 113-115 oC; IR (KBr): 3031, 2947, 2905, 1726, 1642, 1525, 1499, 1239, 759 
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cm-1; MS: m/z = 467 [M]+; Anal. Calcd for C29H26ClN3O4: C, 67.50; H, 5.08; N, 8.14. 
Found: C, 67.19; H, 4.95; N, 7.94%. 
Methyl 1-benzyl-6-chloro-3-[(dipropan-2-ylamino)(oxo)acetyl]-1H-indole-5-carboxyl-
ate (6g). mp 104-106 oC; IR (KBr): 3038, 2979, 2948, 1728, 1638, 1525, 1447, 1253, 778 
cm-1; MS: m/z = 454 [M]+; Anal. Calcd for C25H27ClN2O4: C, 66.00; H, 5.98; N, 6.16. 
Found: C, 65.56; H, 5.87; N, 6.01%. 
 
Methyl 1-benzyl-6-chloro-3-[oxo(pyrrolidin-1-yl)acetyl]-1H-indole-5-carboxylate (6h). 
mp 142-144 oC; Purity by HPLC: 93 %; IR (KBr): 3109, 2981, 2959, 1723, 1618, 1524, 
1448, 1254, 781 cm-1; 1H NMR (300 MHz, CDCl3): δ ppm 1.91-2.02 (m, 4H, 2CH2), 
3.58-3.63 (t, J=6.60 Hz, 2H, CH2), 3.68-3.73 (t, J=6.40 Hz, 2H, CH2), 3.95 (s, 3H, 
OCH3), 5.32 (s, 2H, CH2), 7.15-7.17 (m, 2H, ArH), 7.33-7.38 (m, 4H, ArH), 8.34 (s, 1H, 
ArH), 8.90 (s, 1H, ArH). 13C NMR (75 MHz, CDCl3): δ ppm 19.57, 20.51, 46.19, 47.55, 
51.27, 52.39, 112.75, 114.26, 124.18, 125.06, 126.08, 126.95, 128.30, 129.24, 134.59, 
138.47, 141.16, 163.73, 166.50, 184.43; MS: m/z = 424 [M]+; Anal. Calcd for 
C23H21ClN2O4: C, 65.02; H, 4.98; N, 6.59. Found: C, 64.70; H, 4.83; N, 6.44%. 
 
Methyl 1-benzyl-6-chloro-3-[(2-methylpiperidin-1-yl)(oxo)acetyl]-1H-indole-5-carboxy-
late (6i). mp 90-92 oC; IR (KBr): 3040, 2950, 2918, 1719, 1633, 1521, 1458, 1260, 768 
cm-1; MS: m/z = 452 [M]+; Anal. Calcd for C25H25ClN2O4: C, 66.29; H, 5.56; N, 6.18. 
Found: C, 65.96; H, 5.46; N, 6.02%. 
 
Methyl 1-benzyl-6-chloro-3-[(4-methylpiperidin-1-yl)(oxo)acetyl]-1H-indole-5-carboxy-
late (6j). mp 181-183 oC; IR (KBr): 3016, 2976, 2922, 1710, 1632, 1510, 1444, 1240, 765 
cm-1; MS: m/z = 452 [M]+; Anal. Calcd for C25H25ClN2O4: C, 66.29; H, 5.56; N, 6.18. 
Found: C, 65.93; H, 5.42; N, 6.03%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 6a 
 
IR spectra of compound 6h 
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Mass spectrum of compound 6a 
 
 
Mass spectrum of compound 6h 
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1H NMR spectrum of compound 6a 
 
 
1H NMR spectrum of compound 6h 
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13C NMR spectrum of compound 6a 
 
 
13C NMR spectrum of compound 6h 
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HPLC of compound 6a 
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HPLC of compound 6h 
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Table-6b: Antimicrobial activity of Methyl 1-benzyl-6-chloro-3-[(N,N-dialkylamino) 
 (oxo)acetyl]-1H-indole-5-carboxylates. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
6a 100 100 500 500 200 250 500 
6b 62.5 100 100 100 200 250 250 
6c 200 200 250 250 250 500 1000 
6d 500 500 125 250 500 500 200 
6e 250 500 500 500 250 1000 1000 
6f 100 200 250 100 500 500 1000 
6g 500 250 250 250 1000 500 500 
6h 500 250 500 250 500 250 250 
6i 200 125 100 100 250 500 500 
6j 250 200 200 250 1000 250 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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INTRODUCTION 
6-Chloro-indole-5-carboxamide moieties represent important building blocks in 
both natural and synthetic bioactive compounds, which have been shown to possess 
diverse therapeutic activities. The nature and the position of the substituent on the indole 
moiety influence these activities. Molecules containing 6-chloro-3-
[(diethylamino)(oxo)acetyl]-1H-indole-5-carboxamides have been shown a broad range 
of important biological activities.  
 
N
O
O
R
2
O
NH
R
1
R
3
R1 = aryl, R2 = secondary amine,
R3 = alkyl
(1)  
 
Our strategy is based on to develop a new bioactive entity especially with 
pharmacological activities bearing heterocyclic ring system. Literature survey reveals that 
nitrogen containing heterocyclic compounds like 6-chloro-indole-5-carboxamide have 
received considerable attention in medicinal science due to their biological and 
pharmacological activities.  
 
SYNTHETIC ASPECT 
Various methods for the preparation of indole-5-carboxamide and hydrolysis of 
ester have been cited in literature, some of the methods are as under. 
HYDROLYSIS  
1. J. L. et al.1 have synthesized dihydroindole carboxylic acid ester was hydrolyzed 
to the free acid employing potassium hydroxide in aqueous DMSO.  
 
N
H
COOEt
KOH, DMSO
N
H
O
OH
 
 
2. S. Mattsson et al.2 have synthesized a mild hydrolysis of esters mediated by 
lithium salts.  
 
Studies on heterocyclic… 
Glyoxylamide derivatives…                                                                                          153 
R
1Y
X R
3
R
2
O
O
R
4 R
1Y
X R
3
R
2
OH
O
Et3N, LiBr
CH3CN, H2O
 
 
ACID AMINE COUPLING  
3. An effective protocol for a waste-minimized, environmentally benign thermal 
condensation of carboxylic acids with amines has been identified by L. J. Gooben 
et al.3 
 
R
1
O
OH
+ NH
R
2
R
3
neat, 160OC
2-24 hr.
R
1
N
O
R
2
R
3
 
 
4. Z. Huang et al.4 have prepared borane-tetrahydrofuran complex used to generate 
triacyloxyboranes, which can be effectively reacted with various nucleophiles 
(alkylamines, arylamines, hydrazides, alcohols, phenols) at reflux temperature in 
toluene to provide the corresponding amines.  
 
R
1
O
OH
0.35 eq. BH3-THF
toluene, rt., 1 hr.
R
1
O
O B
1.2 eq. R2R3NH
reflux, 12 hr.
R
1
O
N R
3
R
2
 
 
5. The conversion of carboxylic acids to their corresponding acid chlorides occurs 
rapidly in the presence a tertiary amine base and 3,3-dichlorocyclopropenes via 
aromatic cation-activated nucleophilic acyl substitution to give the corresponding 
amides synthesized by D. J. Hardee and coworkers.5  
 
R
1
O
OH
DIPEA, CH2Cl2 R
1
O
Cl
BnNH2 
15 min.
R
1
O
NHBnClCl
 
 
6. G. E. Veitch et al.6 have used magnesium nitride as a convenient source of 
ammonia allows a direct transformation of esters to primary amides. Methyl, 
ethyl, isopropyl, and tert-butyl esters are converted to the corresponding 
carboxamides in good yields. 
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O R
2 R
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NH2
5 eq. Mg3N2
MeOH, 80OC
 
 
7. C. Larrive-Aboussafy et al.7 have synthesized DBU catalyzed corresponding 
amides derivatives.  
 
Ph OH
O 1.0 - 1.2 eq. CDI
(N,N'-carbonyldiimidazole)
2-methyltetrahydrofuran
Ph
O
N
N
1.1 - 1.5 eq. Ar-NH2
DBU, 2-Me THF
Ph NH
O Ar
 
 
8. Multivalent metal salts, such as ferric chloride and sulfate, are active and versatile 
catalysts for the amidation of aliphatic fatty acids with long-chain aliphatic amines 
was reported by Y. Terada et al.8  
 
O
OH
CH3
+ NH2
2 mol-% FeCl3.6H2O
mesitylene, reflux NHO( )n  
 
9. J. Bures et al.9 have synthesized 2,2′-dipyridyl diselenide catalyzed a direct 
reaction of carboxylic acids with azides and trimethylphosphine at room 
temperature.  
 
R
1
O
OH
+ N3 R
2 Me3P,  2,2'-PySeSePy
toluene, rt.
R
1
O
NH R
2
 
 
10. I. Azumaya et al.10 have prepared various tertiary benzanilide derivatives were 
effectively synthesized in high yields from a broad range substituted benzoic acid 
and N-monoalkylated anilines using dichlorotriphenylphosphorane in chloroform.  
 
Ar N
H
R
1
+
Ar'
O
OH
Ph3PCl2
CHCl3, reflux
Ar N
R
1
O
Ar'
 
 
11. Deoxo-Fluor is a versatile and mild reagent for acyl fluoride generation and 
subsequent one-flask amide coupling. The conversion of acids to amides and 
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weinreb amides and the use of deoxo-fluor as peptide-coupling reagent have been 
explored. Products were isolated after facile purification in good yields by J. M. 
White et al.11 
R
1
R
2
O
OH
+ F3S
OCH3
OCH3
DIPEA
CH2Cl2
R
1
R
2
O
F
NHR3R4
R
1
R
2
O
N
R
3
R
4
 
 
12. D. M. Shendage et al.12 have prepared stereoconservative protection and 
deprotection method of amino and carboxyl groups includes the generation of N-
phthaloyl N'-alkyl secondary amides from N-phthaloyl amino acids by using a 
mixed anhydride method. These secondary amides have been transformed by 
thermal rearrangement of the intermediate nitrosoamides to esters with retention 
of configuration and excellent yields. 
 
PGN
R
1
O
OH
(1) isobutyl chloroformate (IBCF)
MeNH2, RNH2
(2) 5% NaHCO3
PGN
R
1
O
NHR
2
 
 
 
REACTION MECHANISM 
 
R OH
O
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+ C NN C
N
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O
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O+R1 NH2..R C NH
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THERAPEUTIC IMPORTANCE 
From the literature survey, it was revealed that indole carboxamide derivatives (2) 
are better therapeutic agents. B. J. Mavunkel et al.13 have prepared of indolylcarboxamide 
derivatives as inhibitors of p38 kinase.  
 
N
H
MeO
O
N
O
O
N
N
CH3
Ph
(2)  
 
G. Shattat et al.14 have synthesized and evaluated anti-hyperlipidemic activity of 
N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide (3) derivatives. H. B. Rubins and 
coworkers15 have studied indole carboxamide derivatives as pharmacological mechanism 
of fibrates, including bezafibrate, by the induction of lipoprotein lipase and reduction of 
apolipoprotein C-III synthesis leading to increased hydrolysis of triglycerides (TG). S. 
Olgen et al.16 and G. Liu et al.17 have studies the potential role for indole carboxamide 
derivatives as anti-allergics and antioxidants. 
N
H
F
NH
O
O
(3)
 
 
C. Kishor Kumar et al.18 have synthesized 3-oxoisoindoline-5-carboxamides (4) 
and their antioxidant activity studies. K. B. Beckman et al.19 and B. Halliwel et al.20 have 
studied free radicals and active oxygen species have been related with cardiovascular, 
inflammatory diseases and even with a role in cancer. 
 
NH
O
NH
O
R
1
(4)  
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S. Henning et al.21 have reported cyclic indole-3-carboxamides (5), as renin 
inhibitors and renin-angiotensin modulators useful in the treatment of hypertension. C. 
Zhong et al.22 have synthesized and reported antitumor activities of 1H-indole-5-
carboxamide derivatives.  R. Aleksandra et al.23 have documented rational design, 
synthesis, and potency of 1H-indole-5-carboxamide as potential fructose 1,6-
bisphosphatase inhibitors.  
 
N
OH
CH3
CH3
F
O
N NH
(5)
 
 
G.  A. Doherty et al.24 have synthesized indole-5-carboxamide derivatives (6) 
as DP2 receptor modulators for treating immunological diseases. Indole carboxamide 
derivatives applied as p38α-selective MAP kinase inhibitor reduces tumor growth in 
mouse xenograft models of multiple myeloma and SD-282 reduces inflammation in a 
subchronic model to tobacco smoke-induced airway inflammation by S. Medicherla et 
al.25,26  
N
O
OH
CN
O
NHCl
(6)
 
 
H. Timo and coworkers27 have synthesized 1H-indole-5-carboxamide derivatives 
(7) as selective 5-HT1A agonists. S. Medicherla et al.28,29 have synthesized arthritis and 
nonobese diabetic mice with type I diabetes studies of 1H-indole-5-carboxamide 
derivatives. 
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N
H
O
NH2 N
N
OCH3
(7)
 
 
K. L. Leboulluec et al.30 have synthesized 1H-indole-5-carboxamide (8) and 
exhibiting serotonergic binding affinity. Rousseau et al.31 have studied indoline-5-
carboxamide derivatives as antimicrobial agents. Potent nonpeptide GnRH receptor 
antagonists derived from substituted indole-5-carboxamides by W. T. Ashton et al.32  
 
N
H
O
NH2
NH NH
N
H(8)  
 
A. William et al.33 have prepared and formulated of 1H-indole-5-carboxamide (9) 
for treatment of migraine. A. Sunjoo et al.34 have studied bis-indole destabilizes 
microtubules and display potent in vitro and in vivo antitumor activity in prostate cancer. 
N
H
O
NH
N
R
2
R
1
R
3
R
4
(9)  
 
Synthesis and pharmacological evaluation of 1H-indol derivative (10) as potent 
antimitotic agent reported by R. S. Shetty et al.35 B. Gerald et al.36 have synthesized 
indole derivatives and studied  antitumoral activity in vivo, shows efficacy toward 
multidrug-resistant tumor cells, and lacks neurotoxicity. 
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The preparation and evaluation of a novel class of CB2 agonists based on a 
1,2,3,4-tetrahydropyrrolo[3,4-b]indole moiety (11) reported by D. Pagea et al.37  
 
R
1
N
O
N
CH3
R1 = methyl, benzyl, ethylSO2, isopropylSO2 etc
(11)  
 
Thus with an effort to capitalize the biological potential of the heterocyclic system 
and to provide more interesting compounds for biological screening, we have under taken 
the synthesis of several indole-5-carboxamides which has been described as under. 
 
 
PART-II:  STUDIES ON 6-CHLORO-INDOLE-3-YL-GLYOXYLAMIDE 
DERIVATIVES 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-CHLORO-3-
[(DIETHYLAMINO)(OXO)ACETYL]-1-METHYL-N-ARYL-1H-
INDOLE-5-CARBOXAMIDES 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-CHLORO-
3-[(DIETHYLAMINO)(OXO)ACETYL]-1-BENZYL-N-ARYL-1H-
INDOLE-5-CARBOXAMIDES 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-CHLORO-3-
[(DIETHYLAMINO)(OXO)ACETYL]-1-METHYL-N-ARYL-1H-INDOLE-5-
CARBOXAMIDES. 
 
The discovery of indole glyoxylamide derivatives as potent biologically active 
agent has led to the exploration of large number of structural variants, containing 6-
chloro-indole-3-yl-glyoxylamide moiety as an invariable ingredient. In view of these 
reports, we have synthesize 6-chloro-indole-3-yl-glyoxylamide derivatives by the 
condensation of 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxylic 
acid and different aryl amine in the presence of DCC, HOBT and TEA. 
 
REACTION SCHEME 
 
 
 
 
 
 
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in DMSO-d6/CDCl3 solution on a Bruker Ac 400 MHz 
spectrometer. Purity of the synthesized compounds was checked by HPLC Agilent 1100 
series. Elemental analysis of the all the synthesized compounds was carried out on Euro 
EA 3000 elemental analyzer and the results are in agreements with the structures 
assigned.  
 
[A] Preparation of Methyl 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-
indole-5-carboxylate. 
See, Part-B, Part-1, Section-I Experimental Section [B]. 
 
[B] Preparation of Methyl 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-
indole-5-carboxylic acid. 
To a stirred solution of methyl 6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-
1H-indole-5-carboxylate (0.5 g, 1.42 mmol) in MeOH (10 ml), 40% sodium hydroxide (1 
ml) solution was added in solution. The reaction mixture was refluxed for 4 hour and the 
solvent was removed in vacuo. The viscous oil obtained was neutralized with an aqueous 
solution of HCl. The product was extracted with ethylacetate (25 ml × 3), and the 
combined organic layers were washed with water followed by brine and dried over 
anhydrous Na2SO4. The solvent was removed in vacuo, and the solid product was 
obtained. Yield: 85 %, mp 145-147 oC. 
 
[C] General procedure for the preparation of 6-Chloro-3-
 [(diethylamino)(oxo)acetyl]-1-methyl-N-aryl-1H-indole-5-carboxamides. 
    To a stirred cooled (ice bath) solution of 6-chloro-3-
[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxylic acid (0.4 g, 1.19 mmol) in 
dry DCM (10 ml), HOBT (N-hydroxybenzotrizole) (0.24 g, 1.78 mmol) and DCC (N,N'-
dicyclohexylcarbodiimide) (0.36 g, 1.78 mmol) was added in solution at 0 oC. The 
obtained solution was stirred for 15.0 minute at 0 oC. To this solution arylamine (1.19 
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mmol) in dry DCM (5 ml) was added dropwise, then after 2.0 minute TEA (0.33 ml 2.38 
mmol) was added. The reaction mixture was stirred for 10 hour at room temperature 
(monitored by TLC). The solvent was removed in vacuo. The product was extracted with 
ethylacetate (20 ml × 3), and the combined organic layers were washed with water 
followed by brine and dried over anhydrous Na2SO4. The solvent was evaporated under 
vacuum and the residue was purified by column chromatography on silica gel (eluent: 5:5 
= E.A. :Hexane) to obtain pure product. The physical constants of the product are 
recorder in Table-7a. 
 
[D] Biological evaluation of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-N-
aryl-1H-indole-5-carboxamides. 
 Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-7b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies on heterocyclic… 
Glyoxylamide derivatives…                                                                                          163 
Table-7a: Physical constants of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-N-
aryl-1H-indole-5-carboxamides. 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
7a O
CH3
 
C23H24ClN3O4 
 
 
441.90 
 
75 0.60 
7b 
 
 
C23H24ClN3O3 
 
 
425.90 
 
72 0.52 
7c 
CH3 
 
C23H24ClN3O3 
 
 
425.90 
 
76 0.48 
7d CH3
 
C23H24ClN3O3 
 
 
425.90 
 
71 0.51 
7e 
F  
 
C22H21ClFN3O3 
 
 
429.87 
 
78 0.50 
7f F
 
 
C22H21ClFN3O3 
 
 
429.87 
 
79 0.49 
7g 
Cl 
 
C22H21Cl2N3O3 
 
 
446.32 
 
80 0.53 
7h Cl
 
C22H21Cl2N3O3 
 
 
446.32 
 
74 0.56 
7i 
O
CH3  
C24H24ClN3O4 
 
 
453.91 
 
75 0.54 
 
7j 
  
 
C22H22ClN3O3 
 
 
411.88 
 
70 0.55 
 
               TLC solvent system:- E.A. : Hexane  = 5 : 5 
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ANALYTICAL DATA 
6-Chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-methoxyphenyl)-1-methyl-1H-indole-5-
carboxamide (7a). mp 184-186 oC; IR (KBr): 3354 (N-H str), 2949 (C-H str), 2922 (C-H 
str), 1708 (ketone, C=O str), 1645 (amide, C=O str), 1512 (Ar, C=C str), 1465 (Ar, C=C 
str), 1365 (N-H ban), 1249 (C-H ban), 1206 (C-N str), 854 (C-H o.p. ban), 748 (C-Cl str) 
cm-1; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.96-1.23 (m, 6H, 2CH3), 3.24-3.32 (m, 2H, 
CH2), 3.42-3.50 (m, 2H, CH2), 3.67 (s, 3H, CH3), 3.85 (s, 3H, OCH3), 6.52-6.59 (m, 2H, 
ArH), 6.87-7.09 (m, 2H, ArH), 7.23 (s, 1H, ArH), 7.78 (s, 1H, ArH), 8.15 (s, 1H, ArH), 
10.36 (s, 1H, NH). MS: m/z = 441 [M]+; Anal. Calcd for C23H24ClN3O4: C, 62.51; H, 
5.47; N, 9.51. Found: C, 62.16; H, 5.34; N, 9.43%. 
 
N-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-carboxamide 
(7b). mp 125-126 oC; Purity by HPLC: 95 %; IR (KBr): 3321, 2941, 2859, 1707, 1625, 
1527, 1440, 1246, 771cm-1; 1H NMR (400 MHz, DMSO-d6): δ ppm 1.02-1.23 (m, 6H, 
2CH3), 3.22-3.24 (m, 2H, CH2), 3.40-3.44 (m, 2H, CH2), 3.91 (s, 3H, CH3), 4.48 (s, 2H, 
CH2), 7.27-7.38 (m, 5H, ArH), 7.84 (s, 1H, ArH), 8.13 (s, 1H, ArH), 8.22 (s, 1H, ArH), 
8.93 (s, 1H, NH). 13C NMR (75 MHz, CDCl3): δ ppm 13.12, 14.61, 32.63, 34.12, 39.01, 
42.15, 112.32, 114.34, 124.38, 125.12, 125.88, 126.23, 128.90, 129.78, 136.55, 138.11, 
139.43, 143.27, 165.01, 167.39, 186.39; MS: m/z = 425 [M]+; Anal. Calcd for 
C23H24ClN3O3: C, 64.86; H, 5.68; N, 9.87. Found: C, 64.44; H, 5.53; N, 9.75%.  
 
6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-N-(3-methylphenyl)-1H-indole-5-
carboxamide (7c). mp 147-149 oC; IR (KBr): 3340, 2968, 2898, 1711, 1627, 1547, 1473, 
1250, 758 cm-1; MS: m/z = 425 [M]+; Anal. Calcd for C23H24ClN3O3: C, 64.86; H, 5.68; 
N, 9.87. Found: C, 64.51; H, 5.53; N, 9.80%. 
  
6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-N-(4-methylphenyl)-1H-indole-5-
carboxamide (7d). mp 170-171 oC; IR (KBr): 3362, 3020, 2936, 2860, 1716, 1629, 1525, 
1467, 1229, 749 cm-1; MS: m/z = 425 [M]+; Anal. Calcd for C23H24ClN3O3: C, 64.86; H, 
5.68; N, 9.87. Found: C, 64.60; H, 5.59; N, 9.79%. 
 
6-Chloro-3-[(diethylamino)(oxo)acetyl]-N-(2-fluorophenyl)-1-methyl-1H-indole-5-
carboxamide (7e). mp 110-111 oC; IR (KBr): 3349, 3048, 2961, 2819, 1715, 1632, 1521, 
1447, 1263, 763 cm-1; MS: m/z = 430 [M+1]+; Anal. Calcd for C22H21ClFN3O3: C, 61.47; 
H, 4.92; N, 9.78. Found: C, 61.11; H, 4.85; N, 9.60%. 
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6-Chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-fluorophenyl)-1-methyl-1H-indole-5-
carboxamide (7f). mp 118-120 oC; IR (KBr): 3336, 2949, 2945, 1715, 1653, 1517, 1416, 
1233, 761 cm-1; MS: m/z = 430 [M+1]+; Anal. Calcd for C22H21ClFN3O3: C, 61.47; H, 
4.92; N, 9.78. Found: C, 61.13; H, 4.80; N, 9.61%. 
 
6-Chloro-N-(3-chlorophenyl)-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-
carboxamide (7g). mp 140-142 oC; IR (KBr): 3345, 3023, 2947, 2843, 1706, 1633, 1518, 
1440, 1256, 775 cm-1; MS: m/z = 447 [M+1]+; Anal. Calcd for C22H21Cl2N3O3: C, 59.20; 
H, 4.74; N, 9.41. Found: C, 58.91; H, 4.64; N, 9.27%. 
 
6-Chloro-N-(4-chlorophenyl)-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-
carboxamide (7h). mp 160-161 oC; IR (KBr): 3342, 2957, 2926, 1710, 1641, 1528, 1434, 
1228, 783 cm-1; MS: m/z = 448 [M+2]+; Anal. Calcd for C22H21Cl2N3O3: C, 59.20; H, 
4.74; N, 9.41. Found: C, 58.85; H, 4.60; N, 9.29%. 
 
N-(4-Acetylphenyl)-6-chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-1H-indole-5-
carboxamide (7i). mp 168-169 oC; IR (KBr): 3371, 3021, 2974, 2910, 1720, 1636, 1536, 
1462, 1250, 790 cm-1; MS: m/z = 453 [M]+; Anal. Calcd for C24H24ClN3O4: C, 63.50; H, 
5.33; N, 9.26. Found: C, 63.12; H, 5.24; N, 9.10%. 
 
6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-methyl-N-phenyl-1H-indole-5-carboxamide 
(7j). mp 129-130 oC; IR (KBr): 3360, 3055, 2922, 2858, 1705, 1623, 1550, 1414, 1278, 
770 cm-1; MS: m/z = 411 [M]+; Anal. Calcd for C22H22ClN3O3: C, 64.15; H, 5.38; N, 
10.20. Found: C, 63.89; H, 5.29; N, 10.03%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 7a 
 
IR spectra of compound 7b
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Mass spectrum of compound 7a 
 
 
Mass spectrum of compound 7b 
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1H NMR spectrum of compound 7a 
 
 
 
Expanded spectrum of compound 7a 
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Expanded spectrum of compound 7a 
 
 
 
1H NMR spectrum of compound 7b 
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Expanded spectrum of compound 7b 
 
 
 
Expanded spectrum of compound 7b 
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HPLC of compound 7b 
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13C NMR spectrum of compound 7b 
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Table-7b:  Antimicrobial activity of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1- 
        methyl-N-aryl-1H-indole-5-carboxamides. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
7a 250 250 125 200 500 250 500 
7b 200 200 100 200 250 500 1000 
7c 100 100 100 100 250 1000 1000 
7d 500 250 500 500 500 250 250 
7e 250 250 500 250 1000 500 250 
7f 250 500 200 500 1000 1000 500 
7g 250 500 500 250 500 250 250 
7h 62.5 100 50 100 250 500 250 
7i 200 200 100 200 250 500 500 
7j 250 200 100 100 500 1000 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-CHLORO-3-
[(DIETHYLAMINO)(OXO)ACETYL]-1-BENZYL-N-ARYL-1H-INDOLE-5-
CARBOXAMIDES. 
 
6-Chloro-indole-3-yl-glyoxylamide moieties represent important building blocks 
in both natural and synthetic bioactive compounds, which have been shown to possess 
diverse therapeutic activities. Looking to this diversified activities the synthesize of 6-
chloro-indole-3-yl-glyoxylamide derivatives have been undertaken the condensation of 1-
benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1H-indole-5-carboxylic acid and different 
aryl amine in the presence of DCC, HOBT and TEA. 
 
REACTION SCHEME 
 
 
 
 
 
 
 
 
The constitution of all the synthesized compounds have been characterized by 
using elemental analysis, FT-IR, 1H NMR, 13C NMR spectroscopy and further supported 
by mass spectroscopy. Purity of all the compounds has been checked on thin layer 
chromatographic plate and HPLC technique. 
All the synthesized compounds were tested for their antibacterial and antifungal 
activity (MIC) in vitro by broth dilution method with two Gram-positive bacteria, two 
Gram-negative bacteria and three fungal strains. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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EXPERIMENTAL SECTION 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm 
thickness and spots were located by iodine and UV light. IR spectra were recorded on 
Shimadzu FT-IR-8400 instrument using KBr pellet method. Mass spectra were recorded 
on Shimadzu GC-MS-QP-2010 model using direct inlet probe technique. 1H NMR and 
13C NMR was determined in DMSO-d6 solution on a Bruker Ac 400 MHz spectrometer. 
Purity of the synthesized compounds was checked by HPLC Agilent 1100 series. 
Elemental analysis of the all the synthesized compounds was carried out on Euro EA 
3000 elemental analyzer and the results are in agreements with the structures assigned.  
 
 [A] Preparation of Methyl 1-benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1H-
indole-5-carboxylate. 
See, Part-B, Part-1, Section-II Experimental Section [B]. 
 
[B] Preparation of 1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-1H-indole-5-
carboxylic acid. 
To a stirred solution of methyl 1-benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-
1H-indole-5-carboxylate (0.5 g, 1.17 mmol) in MeOH (10 ml), 40% sodium hydroxide (1 
ml) solution was added. The reaction mixture was refluxed for 4 hour and the solvent was 
removed in vacuo. The viscous oil obtained was neutralized with an aqueous solution of 
HCl. The product was extracted with ethylacetate (25 ml × 3), and the combined organic 
layers were washed with water followed by brine and dried over anhydrous Na2SO4. The 
solvent was removed in vacuo, and the solid product was obtained. Yield: 80%, mp 160-
161 oC. 
 
[C] General procedure for the preparation of 6-Chloro-3-
[(diethylamino)(oxo)acetyl]-1-benzyl-N-aryl-1H-indole-5-carboxamides. 
To a stirred cooled (ice bath) solution of 1-benzyl-6-chloro-3-
[(diethylamino)(oxo)acetyl]-1H-indole-5-carboxylic acid (0.4 g, 0.93 mmol) in dry DCM 
(10 ml), HOBT (N-hydroxybenzotrizole) (0.18 g, 1.40 mmol) and DCC (N,N'-
dicyclohexylcarbodiimide) (0.28 g, 1.40 mmol)  was added in solution at 0 oC. The 
obtained soluction was stirred for 15.0 minutes at 0 oC. To this solution arylamine in dry 
DCM (5 ml) was added dropwise, then after 2.0 minute TEA (0.26 ml, 1.87 mmol) was 
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added. The reaction mixture was stirred for 10 hour at room temperature (monitored by 
TLC). The solvent was removed in vacuo. The product was extracted with ethylacetate 
(20 ml × 3), and the combined organic layer was washed with water followed by brine 
and dried over anhydrous Na2SO4. The solvent was evaporated under vacuo and the 
residue was purified by column chromatography on silica gel (eluent: 5:5 = E.A.:Hexane) 
to obtain pure product. The physical constants of the product are recorder in Table-8a. 
 
[D] Biological evaluation of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-benzyl-N-
aryl-1H-indole-5-carboxamides.  
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I, 
antimicrobial activity. The MIC values of the test compounds are recorded in Table-8b. 
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Table-8a: Physical constants of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-benzyl-N-
aryl-1H-indole-5-carboxamides. 
 
 
 
 
 
 
 
Sr. 
No. 
Substitution 
R MF MW Yield (%) Rf value 
8a O
CH3
 
C29H28ClN3O4 
 
 
518.00 
 
76 0.58 
8b 
 
 
C29H28ClN3O3 
 
 
502.00 
 
72 0.54 
8c 
CH3 
 
C29H28ClN3O3 
 
 
502.00 
 
78 0.55 
8d CH3
 
C29H28ClN3O3 
 
 
502.00 
 
73 0.56 
8e 
F  
 
C28H25ClFN3O3 
 
 
505.96 
 
74 0.60 
8f F
 
 
C28H25ClFN3O3 
 
 
505.96 
 
68 0.61 
8g 
Cl 
 
C28H25Cl2N3O3 
 
 
522.42 
 
69 0.54 
8h Cl
 
C28H25Cl2N3O3 
 
 
522.42 
 
70 0.53 
8i 
O
CH3  
C30H28ClN3O4 
 
 
530.01 
 
72 0.55 
 
8j 
  
 
C28H26ClN3O3 
 
 
487.97 
 
73 0.52 
                   
               TLC solvent system:- E.A. : Hexane  = 5 : 5 
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ANALYTICAL DATA 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-methoxyphenyl)-1H-indole-5-
carboxamide (8a). mp 89-91 oC; IR (KBr): 3359, 3023, 2952, 2865, 1717, 1638, 1532, 
1462, 1258, 767 cm-1; MS: m/z = 518 [M]+; Anal. Calcd for C29H28ClN3O4: C, 67.24; H, 
5.45; N, 8.11. Found: C, 66.95; H, 5.40; N, 7.98%. 
 
N,1-Dibenzyl-6-chloro--3-[(diethylamino)(oxo)acetyl]-1H-indole-5-carboxamide (8b). 
mp 120-122 oC; Purity by HPLC: 94 %; IR (KBr): 3394 (N-H str), 3032 (Ar, C-H str), 
2929 (C-H str), 2856 (C-H str), 1708 (ketone, C=O str), 1627 (amide, C=O str), 1519 (Ar, 
C=C str), 1456 (Ar, C=C str), 1300 (N-H ban), 1244 (C-H ban), 794 (C-Cl str) cm-1; 1H 
NMR (400 MHz, DMSO-d6): δ ppm 1.05-1.16 (m, 3H, CH3), 1.16-1.23 (m, 3H, CH3), 
3.24-3.34 (m, 2H, CH2), 3.34-3.43 (m, 2H, CH2), 4.46 (s, 2H, CH2), 5.61 (s, 2H, CH2), 
7.26-7.35 (m, 10H, ArH), 7.83 (s, 1H, ArH), 8.13 (s, 1H, ArH), 8.45 (s, 1H, ArH), 8.98 
(s, 1H, NH). MS: m/z = 504 [M+2]+; Anal. Calcd for C29H28ClN3O3: C, 69.38; H, 5.62; N, 
8.37. Found: C, 68.99; H, 5.53; N, 8.23%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(3-methylphenyl)-1H-indole-5-
carboxamide (8c). mp 97-99 oC; IR (KBr): 3354, 3014, 2977, 1730, 1637, 1523, 1446, 
1230, 777 cm-1; 1H NMR (400 MHz, DMSO-d6): δ ppm 1.05-1.08 (t, J=7.2 Hz, 3H, CH3), 
1.16-1.19 (t, J=7.2 Hz, 3H, CH3), 2.30 (s, 3H, CH3), 3.23-3.28 (q, J=7.2 Hz, 2H, CH2), 
3.42-3.47 (q, J=7.2 Hz, 2H, CH2), 5.64 (s, 2H, CH2), 6.91-6.93 (d, J=7.2 Hz, 1H, ArH), 
7.20-7.22 (m, 1H, ArH), 7.24-7.29 (m, 2H, ArH), 7.31-7.38 (m, 3H, ArH), 7.46-7.48 (d, 
J=8.0 Hz, 1H, ArH), 7.57 (s, 1H, ArH), 7.88 (s, 1H, ArH), 8.21 (s, 1H, ArH), 8.50 (s, 1H, 
ArH), 10.40 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ ppm 13.15, 14.58, 21.69, 
38.67, 42.14, 50.28, 113.07, 113.38, 117.22, 120.49, 121.58, 124.33, 124.90, 126.02, 
127.60, 128.41, 129.07, 129.28, 132.56, 136.90, 137.12, 138.40, 139.43, 141.72, 165.74, 
166.84, 186.65; MS: m/z = 501 [M-1]+; Anal. Calcd for C29H28ClN3O3: C, 69.38; H, 5.62; 
N, 8.37. Found: C, 69.05; H, 5.54; N, 8.25%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-methylphenyl)-1H-indole-5-
carboxamide (8d). mp 115-116 oC; IR (KBr): 3355, 3078, 2941, 2912, 1705, 1646, 1520, 
1468, 1260, 738 cm-1; MS: m/z = 501 [M-1]+; Anal. Calcd for C29H28ClN3O3: C, 69.38; 
H, 5.62; N, 8.37. Found: C, 69.01; H, 5.50; N, 8.20%. 
 
Studies on heterocyclic… 
Glyoxylamide derivatives…                                                                                          179 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(2-fluorophenyl)-1H-indole-5-
carboxamide (8e). mp 170-172 oC; IR (KBr): 3356, 3070, 2911, 2831, 1728, 1626, 1528, 
1432, 1268, 740 cm-1; MS: m/z = 506 [M+1]+; Anal. Calcd for C28H25ClFN3O3: C, 66.47; 
H, 4.98; N, 8.30. Found: C, 66.12; H, 4.88; N, 8.12%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-fluorophenyl)-1H-indole-5-
carboxamide (8f). mp 165-167 oC; IR (KBr): 3344, 3084, 2981, 2901, 1726, 1633, 1520, 
1447, 1246, 786 cm-1; MS: m/z = 506 [M+1]+; Anal. Calcd for C28H25ClFN3O3: C, 66.47; 
H, 4.98; N, 8.30. Found: C, 66.15; H, 4.90; N, 8.21%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(3-chlorophenyl)-1H-indole-5-
carboxamide (8g). mp 145-147 oC; IR (KBr): 3378, 3043, 2934, 2876, 1721, 1651, 1526, 
1446, 1265, 768 cm-1; MS: m/z = 523 [M+1]+; Anal. Calcd for C28H25Cl2N3O3: C, 64.37; 
H, 4.82; N, 8.04. Found: C, 63.98; H, 4.69; N, 7.89%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-(4-chlorophenyl)-1H-indole-5-
carboxamide (8h). mp 137-138 oC; IR (KBr): 3338, 3019, 2942, 2836, 1716, 1646, 1545, 
1435, 1248, 757 cm-1; MS: m/z = 524 [M+2]+; Anal. Calcd for C28H25Cl2N3O3: C, 64.37; 
H, 4.82; N, 8.04. Found: C, 64.02; H, 4.75; N, 7.91%. 
 
N-(4-Acetylphenyl)-1-benzyl-6-chloro--3-[(diethylamino)(oxo)acetyl]-1H-indole-5-
carboxamide (8i). mp 85-86 oC; IR (KBr): 3368, 3040, 2935, 2840, 1708, 1630, 1562, 
1451, 1216, 791 cm-1; MS: m/z = 529 [M-1]+; Anal. Calcd for C30H28ClN3O4: C, 67.98; 
H, 5.32; N, 7.93. Found: C, 67.61; H, 5.23; N, 7.77%. 
 
1-Benzyl-6-chloro-3-[(diethylamino)(oxo)acetyl]-N-phenyl-1H-indole-5-carboxamide 
(8j). mp 104-106 oC; IR (KBr): 3350, 3015, 2919, 2860, 1710, 1633, 1548, 1460, 1232, 
762 cm-1; MS: m/z = 487 [M]+; Anal. Calcd for C28H26ClN3O3: C, 68.92; H, 5.37; N, 8.61. 
Found: C, 68.55; H, 5.30; N, 8.48%. 
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SPECTRAL STUDY OF SYNTHESIZED COMPOUNDS 
IR spectra of compound 8b 
 
IR spectra of compound 8c 
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Mass spectrum of compound 8b 
 
Mass spectrum of compound 8c 
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1H NMR spectrum of compound 8b 
 
 
Expanded spectrum of compound 8b 
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Expanded spectrum of compound 8b 
 
 
1H NMR spectrum of compound 8c 
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Expanded spectrum of compound 8c 
 
 
Expanded spectrum of compound 8c 
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HPLC of compound 8b 
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13C NMR spectrum of compound 8c 
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Table-8b: Antimicrobial activity of 6-Chloro-3-[(diethylamino)(oxo)acetyl]-1-benzyl-
       N-aryl-1H-indole-5-carboxamides. 
 
Sr. 
No. 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
8a 100 100 250 250 1000 1000 1000 
8b 62.5 100 50 200 1000 1000 500 
8c 200 250 100 100 500 500 1000 
8d 200 200 200 12.5 500 500 500 
8e 100 10 100 50 250 250 250 
8f 500 500 500 250 200 500 1000 
8g 200 200 250 200 500 250 250 
8h 100 100 50 62.5 250 500 500 
8i 250 200 100 200 1000 500 250 
8j 500 500 200 250 500 200 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
S.aureus S.pyogenus E.coli P.aeruginosa 
(microgramme/ml) 
Gentamycin 0.25 0.5 0.05 1 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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